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Abstract 
MARGARET ELIZABETH DUNCAN: Characterization of mechanisms of antibiotic 
resistance in Neisseria gonorrhoeae 
(Under the direction of Robert A. Nicholas, PhD) 
 
Neisseria gonorrhoeae is a Gram-negative diplococcus that causes the sexually 
transmitted infection, gonorrhea. As a naturally competent organism, N. gonorrhoeae can 
take up genetic material from outside the cell and incorporate it into its own DNA 
through homologous recombination. This has allowed the pathogen to generate antigenic 
diversity for escape from the human immune system and to develop and spread antibiotic 
resistance genes. This mode of resistance, chromosomally mediated resistance, is 
complex and requires at least five resistance determinants. Four of these determinants 
have been identified at the molecular level: penA (mutations in penicillin-binding protein 
2 [PBP 2]), mtrR (overexpression of the MtrC-MtrD-MtrE efflux pump), penB (mutations 
in PorB1b), and ponA (mutation in PBP 1). These determinants can be readily transferred 
from a penicillin-resistant donor (FA6140) to a susceptible recipient strain (FA19). 
However, despite repeated attempts, transformation to high-level penicillin resistance 
equivalent to the donor strain has not been achieved.  
I initiated studies to further elucidate the complex mechanisms of chromosomally 
mediated antibiotic resistance in N. gonorrhoeae. First, I characterized unique mutations 
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in mtrR and penB found in a group of clinical isolates from New Caledonia. These 
mutations proved to have weaker phenotypes than the more common mutations. I also 
identified a set of 67 genes found only in penicillin-resistant strains of N. gonorrhoeae. 
When transformed into a penicillin-sensitive strain, none of the genes increased 
resistance. Finally, I initiated studies to elucidate the mechanisms of high-level penicillin 
resistance and to characterize “Factor X”, the unknown gene(s) that is (are) responsible 
for high-level resistance. My results indicate that the phenotype of Factor X is 
independent of the other four resistance determinants and is expressed phenotypically 
even in the absence of other determinants.  Additionally, Factor X plays a role in 
increasing resistance to bactericidal, but not bacteriostatic, antibiotics, reminiscent of 
studies in E. coli whereby bactericidal antibiotics, no matter what pathway they inhibit, 
kill bacteria through a common oxidative stress mechanism. Together, the results of these 
studies add to our knowledge about the interactions between N. gonorrhoeae and 
antimicrobials, and further our understanding of resistance mechanisms. 
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 Chapter 1 
Introduction 
1.1 Introduction 
Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection, 
gonorrhea. Gonococcal infections are the second most commonly reported sexually 
transmitted infections to the Centers for Disease Control, with over 300,000 cases 
reported in 2010. The bacterium infects both men and women, usually causing localized 
infections of the genital tract (McCormack, Stumacher et al. 1977; Sherrard and Barlow 
1996). If left untreated, it can lead to more serious complications including pelvic 
inflammatory disease, ectopic pregnancy, and infertility in women, as well as 
disseminated gonococcal infections in both sexes (Paavonen 1998; Bleich, Sheffield et al. 
2012). N. gonorrhoeae is an obligate human pathogen that has developed multiple 
mechanisms to escape the immune system and resist killing by antimicrobial agents. 
Resistance to nearly all classes of antibiotics has developed, making infections with N. 
gonorrhoeae increasingly difficult to treat. 
 
1.2 Epidemiology 
The Gonococcal Isolate Surveillance Project (GISP) is the CDC program 
designed to collect data regarding numbers of infections and antibiotic susceptibility of 
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Neisseria gonorrhoeae isolates in the United States (Schwarcz, Zenilman et al. 1990). In 
2010, there were 309,341 cases of gonorrhea reported to the CDC. For the first time since 
2006, this represented an increase in the rates of infection. Rates of infection are the 
highest among adolescents and young adults, minorities, and women (Figure 1.1). 
Southern states have the highest rates of infection, consistent with reports from previous 
years (Figure 1.2). The increase in infections in 2010 was broad; nearly all regions of the 
country reported more gonococcal infections, with only the Midwest reporting a 
decrease. There were more men and women of all races/ethnicities infected. The highest 
increase was seen among adults aged 20-24. Because females with gonorrhea are often 
asymptomatic, they can be unknowing carriers of the bacteria (males can also be 
asymptomatic, but this occurs at a much lower rate than females). Thus estimates of the 
actual disease burden may be up to twice as high as the reported number. 
Estimating the number of worldwide gonococcal infections is a challenging task. 
In 2005, the World Health Organization estimated that there were nearly 95 million new 
cases of gonorrhea, with the majority of cases occurring in Southeast Asia and Sub-
Saharan Africa (World Health Organization 2009). The numbers of cases reported in the 
2005 study are much higher than the 1995 and 1999 WHO estimates (Table 1.1) (World 
Health Organization 2001). While some of the increases are due to increased rates of 
infection, officials also believe that the 2005 estimates are more accurate due to better 
data collection between 2000-2005. The 1995 and 1999 values were most likely very 
conservative estimates. 
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Figure 1.1 N. gonorrhoeae infections among various age groups, gender, and race 
Bar graphs representing the rates of infection among age groups, gender, and races in the 
United States, 2010. Rates of infection are the highest among young adults, women, and 
blacks. Infection rates per 100,000 people are shown. 
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Figure 1.2 Geographical distribution of gonorrhea infections across the United 
States 
Bar graph showing rates of infection (per 100,000 people) across the United States. The 
map shows states with higher rates of infection in darker colors. (Map adapted from 
(Centers for Disease Control and Prevention 2011) 
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 Table 1.1 WHO estimation of gonorrhea infections worldwide, 1995, 1999 and 2005. 
Table comparing data collected by the World Health Organization in 1995, 1999, and 2005. Estimated numbers (in millions) of 
gonococcal infections in different regions worldwide are shown. Numbers of infections in 2005 are significantly higher, 
perhaps because of more accurate measurements as well as an increase in the rates of infections (World Health Organization 
2001; World Health Organization 2009). 
 
Region 1995 1995 2005 Region 
North America 1.75 1.56 0.7 North America 
Latin America and 
Caribbean 
7.12 7.27 8.8 Latin America and 
Caribbean 
Europe and Central 
Asia 
3.55 4.42 12 Europe and Central 
Asia 
South and Southeast 
Asia 
29.11 27.20 22.7 South and Southeast 
Asia 
East Asia and 
Australia/New 
Zealand 
3.40 3.39 26.9 East Asia and Pacific 
North Africa and 
Middle East 
1.54 1.47 6.5 North Africa and 
Middle East 
Sub-Saharan Africa 15.67 17.03 17.3 Sub-Saharan Africa 
Total 62.14 62.34 94.9 Total 
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1.3 Clinical Manifestations 
Infections with N. gonorrhoeae are typically localized to mucosa of the genital 
tract, but they can cause serious complications in other body parts. Mucosal infections 
can also occur in other areas. 
 
1.3.1 Genital infections 
Men infected with N. gonorrhoeae typically show symptoms of urethritis. The 
majority of men report urethral discharge only, while others suffer from dysuria or a 
combination of both symptoms (Spence 1983) Interestingly, patients co-infected with 
Chlamydia trachomatis are less likely to display symptoms than those infected with N. 
gonorrhoeae alone (Sherrard and Barlow 1996; Bozicevic, Fenton et al. 2006). Because 
the two bacteria are often found in the same populations, individuals infected are at risk 
for being undiagnosed and further spreading disease. The incubation period for urethral 
N. gonorrhoeae in the male is approximately one week, though a small number (<10%) 
of men with gonococcal urethritis remain asymptomatic (Handsfield, Lipman et al. 1974; 
McNagny, Parker et al. 1992; Sherrard 1996). Because they have no symptoms, these 
men do not seek treatment and the bacterium persists, putting sexual partners at risk for 
infection. 
Localized complications of male urethral gonorrhea can occur. The most common 
complication is epididymitis, with testicular pain and swelling as the predominant 
symptoms (Berger, Alexander et al. 1979; Holmes, Berger et al. 1979). The periurethral 
glands can become infected, resulting in abscesses and penile masses (Fan 2010; Kenfak-
Foguena, Zarkik et al. 2010; Parashar and Schechtman 2011). General penile edema is 
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another possible complication. Other rare complications include urethral stricture, acute 
and chronic prostatitis, perineal swelling from infection of Cowper’s glands, seminal 
vesiculitis, urethral fistulae, and penile sclerosing lymphangitis (Pandhi and Reddy 2002; 
Rosen and Hwong 2003; Marrazzo 2009; Parashar and Schechtman 2011).   
Women infected with N. gonorrhoeae are often asymptomatic or do not seek 
treatment for symptoms (Platt, Rice et al. 1983). The endocervical canal is often infected 
and abnormal, purulent vaginal discharge may be the only presenting symptom 
(McCormack, Stumacher et al. 1977). Other symptoms might include dysuria and 
abnormal vaginal bleeding (Brunham, Paavonen et al. 1984). Symptoms usually develop 
within 3-10 days of exposure, or not at all (Nolan and Osborne 1973; McCormack, 
Stumacher et al. 1977; Platt, Rice et al. 1983). In fact, up to 80% of women infected with 
gonorrhea remain asymptomatic or do not seek treatment for their mild, non-specific 
symptoms (Pedersen and Bonin 1971; Nolan and Osborne 1973; McCormack, Stumacher 
et al. 1977; Spence 1983). These women remain at risk for further complications and also 
pose a public health risk as carriers of the bacterium. 
As with men, the female urethra and periurethral glands may become infected. 
Complications include abscesses of Bartholin’s glands (Nolan and Osborne 1973). By far 
the most common sequela is ascending infection, resulting in Pelvic Inflammatory 
Disease (Swasdio, Rugpao et al. 1996).  
 
1.3.2 Anorectal infections 
 Anorectal gonorrhea infections are possible in both men and women, either 
through direct sexual contact or contamination from secretions from a urethral or cervical 
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infection. As with other gonococcal infections, anorectal infections are often 
asymptomatic (Quinn, Stamm et al. 1983; Turner, Rogers et al. 2002). When symptoms 
are present, anal pruritus, tenesmus, discharge, constipation, and bleeding are the 
common complaints (Miller 2006). Those infected through direct anal intercourse are 
more likely to develop symptoms (Marcus, Bernstein et al. 2010).  
 
1.3.3 Pelvic inflammatory disease 
 Pelvic inflammatory disease (PID) can develop if cervical infection with N. 
gonorrhoeae is not identified and treated. N. gonorrhoeae and Chlamydia trachomatis 
are the most common pathogens associated with PID, though respiratory pathogens and 
endogenous bacteria from the vagina and colon have also been implicated in PID 
pathogenesis (McCormack, Nowroozi et al. 1977; Soper 1994; Ness, Kip et al. 2005). It 
is estimated that PID occurs in approximately 10-40% of women with gonorrhea 
(Paavonen 1998; Walker and Sweet 2011). Vaginal douching greatly increases the 
likelihood of the development of PID (Wolner-Hanssen, Eschenbach et al. 1990; Scholes, 
Daling et al. 1993; Ness, Hillier et al. 2005). PID may be asymptomatic for months or 
years in up to 85% of cases, leading to increased chances of further complications (Hillis, 
Joesoef et al. 1993; Walker and Sweet 2011). As the pathogen ascends from the cervix 
into the uterus and fallopian tubes, acute salpingitis and endometritis can ensue (Holmes, 
Eschenbach et al. 1980; Westrom 1980). Other possible clinical manifestations include 
tubo-ovarian abscesses and pelvic peritonitis. Bilateral pelvic pain, fever, discharge, and 
bleeding are possible symptoms. Low abdominal pain is common, with or without signs 
of a lower genital tract infection (Peipert and Soper 1994). Perihepatitis may develop if 
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the liver capsule is exposed to N. gonorrhoeae from the fallopian tubes (Lopez-Zeno, 
Keith et al. 1985). Damage to the fallopian tubes often occurs, causing infertility in 
approximately 15-20% of patients with PID (Westrom, Joesoef et al. 1992). Multiple 
cases of PID significantly increase the chance of infertility (Paavonen 1998). Tubal 
scarring leads to ectopic pregnancy in 9% of patients with PID, to chronic pelvic pain in 
27% (Westrom, Joesoef et al. 1992; Haggerty, Schulz et al. 2003; Walker and Sweet 
2011).  
 
1.3.4 Infections of the oro-pharynx 
 Neisseria gonorrhoeae can colonize the oro-pharynx but is usually either mild or 
asymptomatic. In fact, less than 10% of those infected seek treatment for symptoms 
(Morris, Klausner et al. 2006). When symptoms are present, a sore throat and dysphagia 
are the complaints (Wiesner, Tronca et al. 1973; Tice and Rodriguez 1981). There may 
be pharyngeal exudates and associated lymphadenopathy on the physical exam. Oro-
pharyngeal infection is most often, but not always, accompanied by a co-existing 
urogenital infection (Gunn, O'Brien et al. 2008)  
 Because symptoms are usually absent, those infected with pharyngeal N. 
gonorrhoeae are possible carriers of the pathogen. As many as 5% of homosexual men 
are infected with pharyngeal gonorrhea (Morris, Klausner et al. 2006). These silent 
pharyngeal infections can serve as a source for urogenital and anorectal infections 
(Kinghorn 2010). Pharyngeal gonorrhea is also a potential source for disseminated 
gonococcal infection in the host. 
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1.3.5 Disseminated gonococcal infection 
 Disseminated gonococcal infection is a rare complication of gonorrhea. In 
approximately 0.5-3% of cases, N. gonorrhoeae spreads from the mucosal surface to 
other body parts, usually the skin and joints (Holmes, Counts et al. 1971; Kerle, Mascola 
et al. 1992). The arthritis-dermatitis syndrome that is most common begins with joint 
pain that involves the knees and elbows, though it may affect other joints (Guillot, 
Delattre et al. 2012). A characteristic skin rash develops with pustules on the extremities 
(Nolan and Osborne 1973). Finally, septic arthritis of one joint develops (Rice 2005). As 
mentioned above, the pharynx is a possible source of the pathogen in cases of DGI 
(Wiesner, Tronca et al. 1973). Thus the patient may or may not have first developed 
symptoms of a urogenital infection. Women are more likely to be affected by DGI, and 
the risk of dissemination is highest after menstruation and while pregnant (O'Brien, 
Goldenberg et al. 1983; Burgis and Nawaz 2006). Patients with deficiencies in the 
complement cascade pathway are also at an increased risk for DGI (Ellison, Curd et al. 
1987). DGI during pregnancy increases the risks of miscarriage, preterm labor, and 
perinatal morbidity and mortality (Burgis and Nawaz 2006; Bleich, Sheffield et al. 2012).  
 While the arthritis-dermatitis syndrome is the most common manifestation of 
DGI, other more serious conditions are possible. Bacterial endocarditis is a rare 
complication, usually involving the aortic valve (50%) or mitral valve (30%) (Jackman 
and Glamann 1991; Akkinepally, Douglass et al. 2010). Ascending aortitis and aortic 
aneurysm have also been reported (Woo, Rabkin et al. 2011). Other possible fatal 
manifestations of DGI are gonococcal meningitis, septicemia, and respiratory distress 
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syndrome (Holmes, Counts et al. 1971; Handsfield 1975; Belding and Carbone 1991; 
Billings, Evans et al. 1991; Thiery, Tankovic et al. 2001).  
 
 
1.3.6 Primary cutaneous infection 
 While rare, it is possible to acquire a gonococcal infection of the skin, even 
without any mucosal surface being infected. These infections are typically found in the 
genital region or on the finger and occur through inoculation of a preexisting lesion. They 
vary in appearance, from pyogenic granulomas to pustules, and can result in localized 
cellulitis (Scott and Scott 1982; Ghosn and Kibbi 2004). 
 
1.3.7 Ocular infection 
 Infection of the eye with N. gonorrhoeae causes conjunctivitis. It is uncommon 
and usually results from autoinoculation, but can also be a result of direct inoculation 
from a sexual partner. Occupationally acquired gonococcal conjunctivitis has been 
reported in laboratory workers (Dillard 2011) Community outbreaks of gonococcal 
conjunctivitis have been reported in Australia and Africa (Mikru, Molla et al. 1991; 
Merianos, Condon et al. 1995; Matters, Wong et al. 1998; Mak, Smith et al. 2001). In a 
1997 outbreak in Australia, the strain involved in the eye infections was not the same 
strain causing genital infections in the region, indicating that factors other than auto-
inoculation or sexual contact were involved in the spread of the disease (Mak, Smith et 
al. 2001). Mucopurulent exudate, photophobia, and pain are characteristic of the infection 
(Day, Ramkissoon et al. 2006). Because the pathogen is able to successfully penetrate the 
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corneal epithelium, the condition can rapidly progress and result in keratoconjunctivitis, 
with subsequent corneal ulceration and even corneal perforation (Tjia, van Putten et al. 
1988). If treatment is not sought quickly, blindness is likely (Tong, Tan et al. 2004; 
Tipple, Smith et al. 2010). 
 
1.3.8 Neonatal infections 
Pregnant women infected with N. gonorrhoeae can transmit the infection to 
neonates during delivery (Cates and Alexander 1988). During delivery, the infant is 
exposed to both the infected cervix and also directly to the bacterium (Shore and 
Winkelstein 1971). Transmission typically results in gonococcal conjunctivitis (Woods 
2005). Pneumonia, arthritis, pharyngitis, and rectal infections are also possible but not as 
common (Gregory, Chisom et al. 1972; Handsfield, Hodson et al. 1973; Alexander 1988). 
Gonococcal scalp abscesses have been reported in newborns at the site of placement of 
intrauterine fetal scalp electrodes (Plavidal and Werch 1977; Reveri and Krishnamurthy 
1979). Because the immune system is not fully developed in newborns, infections can 
progress rapidly from direct inoculation of bacteria into sub-cutaneous tissue. If not 
treated, the newborn can develop serious complications such as osteomyelitis, meningitis, 
or septicemia (Asnis and Brennessel 1992). Because of increased prenatal care, including 
screening for N. gonorrhoeae and the widespread routine use of prophylaxis for newborn 
gonococcal conjunctivitis, neonatal gonococcal infections are far less common today than 
in the past (Hammerschlag, Cummings et al. 1989; Laga, Meheus et al. 1989; Zuppa, 
D'Andrea et al. 2011).   
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1.4 History of gonorrhea 
Neisseria gonorrhoeae is an obligate human pathogen. In fact, there is evidence 
suggesting that the pathogen has been infecting humans for thousands of years. 
Hippocrates described infections resembling male gonococcal urethritis and ancient 
Chinese writings have been recovered describing similar. Several books of the Old 
Testament, including Genesis, Leviticus, and Numbers, describe a condition that is likely 
gonorrhea. Interestingly, the Greek physician Galen gave the disease the name gonorrhea 
(“flow of seed”) in 130AD, but the disease was often confused with syphilis until much 
later. In 1879, microbiologist Albert Neisser definitively identified the causative 
organism, Neisseria gonorrhoeae. 
 Effective therapeutics were not available until the mid-20th century, when the 
sulfonamides were introduced (Cokkinis 1937). Earlier treatment attempts included the 
application of heat, “anti-toxins”, vaccines made up of killed gonococci, mercury, 
irrigation, catheterization, electrolysis, suction, and ingestion of systemic purgatives 
(Broughton 1821; Anonymous 1845; M'Vail D 1884; Stockman 1911; Cambell 1916; 
Russ 1917; Statham 1928; Kanner 1932; Burke, Gabe et al. 1938). 
 
1.5 Transmission and public health recommendations 
 The transmission efficiency of gonorrhea depends on the anatomic site of 
infection and on the type of contact between infected individuals. Male-to-female 
transmission is likely more efficient than female-to-male, resulting in a risk of 
approximately 50-70% per sexual episode (Lin, Donegan et al. 1998). The risk of a 
woman passing the infection to a male urethra during vaginal intercourse is 
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approximately 20% per sexual episode. However, this risk increases to 60-80% after four 
or more exposures (Holmes, Johnson et al. 1970; Hooper, Reynolds et al. 1978). Studies 
have shown that gonorrhea may be passed to the male urethra from the pharynx during 
fellatio, but the rate of transmission is unknown (Tice and Rodriguez 1981; Lafferty, 
Hughes et al. 1997; Janier, Lassau et al. 2003; Bernstein, Stephens et al. 2009). Anal 
transmission is likely efficient, though this has not been quantified. 
 Individuals with significant symptoms of disease are most likely to seek treatment 
for infection, limiting their ability to spread the bacterium. As mentioned above though, 
up to 10% of men and 80% of women do not display signs of early genital infection, 
allowing them to serve as reservoirs of infection for the sexually active population. 
Screening of sexually active young women at annual exams has helped to bring down the 
numbers of gonococcal infections in the United States since the mid-1970’s. Men who 
have sex with men (MSM) should also be screened for rectal and pharyngeal infection, as 
these sites are often asymptomatic but serve as sources for genital infections.  
 
1.5.1 Gonorrhea and other STIs 
 Individuals infected with N. gonorrhoeae are at risk for other sexually transmitted 
infections (STIs). The CDC recommends that all people being treated for gonorrhea also 
receive treatment for Chlamydia trachomatis infections (Marrazzo 2009). In 2000, the 
CDC found that nearly half of all 15-19 year olds infected and almost 40 percent of 20-24 
year olds with gonorrhea were also infected with chlamydia (Dicker, Mosure et al. 2003). 
A similar study among men in Italy showed that nearly half of the men diagnosed with 
gonococcal urethritis were also infected with C. trachomatis (Donati, Di Francesco et al. 
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2009). In 2005, a study showed a high number of cases of concurrent gonorrhea and 
trichomonas, gonorrhea and chlamydia, or gonorrhea, trichomonas, and chlamydia 
(Khan, Fortenberry et al. 2005). A recent study among men in India found a strong 
association between infection with gonorrhea and syphilis, as well as weaker associations 
between gonorrhea and Candida albicans, chancroid, and herpes. Women in the same 
study had co-infections of N. gonorrhoeae and C. albicans, C. trachomatis, or 
Trichomonas vaginalis (Bala, Mullick et al. 2011). While the rates of co-infection with 
specific pathogens vary among locations, it is clear that infection with N. gonorrhoeae 
increases the chances that a patient will be infected with another STI. This is one of the 
reasons that gonococcal infections must be diagnosed and treated with effective 
antibiotics.  
 
1.5.2 N. gonorrhoeae and HIV 
 An additional that N. gonorrhoeae poses a public health risk is because 
individuals infected with the bacterium have an increased likelihood of both transmitting 
and acquiring human immunodeficiency virus (HIV). Individuals infected with both 
gonorrhea and HIV experience increased viral shedding because of increased localized 
expression of the virus (Chen, Boulton et al. 2003). Treatment of gonococcal urethritis 
causes a decrease in HIV viral concentration in semen (Cohen, Hoffman et al. 1997). 
Exposure of primary resting CD4(+) T cells to N. gonorrhoeae increases the likelihood 
that these cells will be infected by HIV-1 (Ding, Rapista et al. 2010). Clearly, the synergy 
between HIV and N. gonorrhoeae is an important public health issue and several 
problematic scenarios are apparent: 1) an individual is infected with gonorrhea and 
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exposed to HIV (increased likelihood of acquiring HIV). 2) An individual infected with 
HIV and exposed to gonorrhea (increased likelihood of acquiring gonorrhea) 3) An 
individual infected with both gonorrhea and HIV exposes another person to both 
pathogens (partner is at risk for both HIV and gonorrhea). 
 
1.6 Biology of the gonococcus 
N. gonorrhoeae belongs to the genus Neisseria, which includes 12 species that 
colonize human mucosal surfaces. The only other pathogenic species in the genus is 
Neisseria meningitidis, the causative agent of bacterial meningitis. N. gonorrhoeae is an 
obligate human pathogen that has evolved with man over thousands of years.   
N. gonorrhoeae is a gram-negative diplococcal organism. Strict growth 
requirements in culture include a temperature of 35-37°C and approximately 5% 
atmospheric CO2 (Spence, Wright et al. 2008). Bicarbonate can be substituted for CO2 
(Morse and Bartenstein 1974). The bacterium thrives in a humid environment. N. 
gonorrhoeae typically grows aerobically but can also grow anaerobically if nitrite is 
provided (Knapp and Clark 1984). Because the organism has complex nutritional needs, 
special media have been developed for growing it in the laboratory. N. gonorrhoeae 
requires iron for growth and is usually able to extract it from the human host; therefore 
iron must be supplemented in the culture medium. Media must also be supplemented with 
glucose, lactate, or pyruvate as these provide a carbon source for the pathogen (Catlin 
1973). Kellogg’s Supplements are often added to the media to meet the nutritional 
requirements (Kellogg, Peacock et al. 1963). Colonies appear on agar plates within 12-48 
hours, but viability decreases dramatically after 48 hours. Growth in liquid culture is 
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difficult. The doubling time is approximately one hour in liquid, but cells have a tendency 
to die for no apparent reason.  
Four different colony morphologies are noticeable on agar plates. As detailed 
below, N. gonorrhoeae expresses opacity proteins (Opa) and a type IV pilus (Tfp) in a 
phase variable manner. Thus at any given time, colonies may be piliated (P+) and may 
appear opaque in color (Opa+). Colony types 1 and 2 are small, shiny, and convex due to 
the expression of the pilus in these types. Piliated colonies may spontaneously lose the 
pili and appear dull and flat, as in colony types 3 or 4 (Kellogg, Peacock et al. 1963). 
Colonies expressing opacity proteins (Opa+) appear yellowish and darker, while Opa- 
colonies are translucent (Walstad, Guymon et al. 1977).  
 
1.6.1 Structure 
N. gonorrhoeae has the structure of a typical gram-negative bacterium. The cell 
wall is composed of an outer membrane and an inner membrane that are separated by a 
thin layer of peptidoglycan. The outer membrane contains several proteins, 
phospholipids, and lipooligosaccharide, all of which are important for the biology of the 
organism. 
 
1.6.1.1 Lipooligosaccharide 
 Lipooligosaccharide (LOS) is an important component of the outer membrane of 
N. gonorrhoeae and contributes to the virulence of the bacterium. All gram-negative 
organisms express lipopolysaccharides (LPS). These glycolipids help to maintain the 
structure of the outer membrane and also serve as virulence factors. The structure of LPS 
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consists of a Lipid A moiety to serve as an anchor to the membrane, a core 
oligosaccharide, and a polymer of a repeating polysaccharide. In contrast, the LOS in 
Neisseria species contains a truncated non-repeating oligosaccharide in place of the 
repeating polysaccharide. (Figure 1.3) (Griffiss, Schneider et al. 1988; Banerjee, Wang et 
al. 1998).  
 The structure of LOS expressed by the gonococcus is variable. During infection, 
different sugars are attached to the core, depending on which LOS biosynthetic proteins 
are expressed (Yang and Gotschlich 1996). The length and composition of the side chains 
varies widely, because the LOS biosynthetic enzymes are highly phase variable 
(Mandrell, Schneider et al. 1986; Griffiss, O'Brien et al. 1987; Gibson, Webb et al. 1989; 
Gibson, Melaugh et al. 1993; Yamasaki, Kerwood et al. 1994). The family of genes that 
transfer sugar residues, the lgt genes, are highly phase variable. Single nucleotide 
insertions within the poly-C or poly-G repeats in the lgt genes are a result of slip-strand 
mispairing during replication (Gotschlich 1994; Danaher, Levin et al. 1995; Yang and 
Gotschlich 1996; Banerjee, Wang et al. 1998). This allows the genes to be turned “on” or 
“off” quickly, ultimately resulting in various side chains attaching to the LOS core. 
Additionally, several promoters are found within the cluster of genes that encode for the 
glycosyltransferases, contributing to further variation in the LOS expression at any time 
(Braun and Stein 2004). The side changes can undergo spontaneous conversion at any 
time when the cell begins to express different glycosyltransferases, allowing a single cell 
to alter its LOS production. Hybrid genes are created by recombination of the different 
glycosyltransferase genes, contributing to antigenic diversity (Tong, Arking et al. 2002). 
Additional variation occurs upon sialyation of the LOS core sugars (Kim, Zhou et al. 
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1992; van Putten and Robertson 1995). Sialyation of LOS contributes to the ability of the 
bacterium to evade immune system defenses (Schneider, Griffiss et al. 1985; Smith, 
Parsons et al. 1995).  
 
1.6.1.2 Opa 
 Opacity associated proteins (Opa) are another set of highly variable proteins 
found in the outer membrane of N. gonorrhoeae (Swanson 1978; Swanson 1978; 
Lambden, Heckels et al. 1979). Gonococci typically encode the information for 11 Opa 
proteins but only express up to 3 at a time (Black, Schwalbe et al. 1984; Connell, Shaffer 
et al. 1990). Expression of the different Opa proteins occurs at the translational level, by 
frame-shifts that occur among the opa genes due to varying numbers of repeats of the 
leader sequence (Stern, Brown et al. 1986).The strength of the promoter also contributes 
to phase variation (Belland, Morrison et al. 1997). Hypervariable (HV) regions of the opa 
genes contribute to the antigeneic diversity seen among expressed Opa proteins (Connell, 
Shaffer et al. 1990). Differential expression of Opa proteins can be found among isolates 
of the same strain. 
Opa proteins can be divided into two groups, depending on the human cellular 
receptor to which they bind (Dehio, Gray-Owen et al. 1998). Most Opa proteins interact 
with the carcinoembryonic antigen-related family of cell adhesion molecules (CEACAM) 
(Wang, Gray-Owen et al. 1998). The other class of Opa proteins binds host cell heparin 
sulfate proteoglycans (HSPG) (van Putten, Duensing et al. 1998).  
Opa proteins are made up of 8 antiparallel β-strands that form a barrel in the outer 
membrane. This part of the protein remains relatively conserved throughout the family. 
 20 
 
Four extracellular loops link the β-strands of the barrel together, and loops 2 and 3 
contain the HV regions of the protein (Sadarangani, Pollard et al. 2011). Opa+ bacterial 
cells are almost always present in natural gonococcal infection. The only time that mainly 
Opa- cells are recovered is during female menses (James and Swanson 1978; Swanson, 
Barrera et al. 1988; Jerse, Cohen et al. 1994). 
 
1.6.1.3 Pili 
Type IV pili (Tfp) are found protruding from the outer membrane of N. 
gonorrhoeae. Tfp are relatively conserved in different gram-negative bacteria and are 
important for pathogenesis, motility, and transformation (Strom and Lory 1993; Craig, 
Pique et al. 2004). Several different proteins are associated with Tfp structure and 
biogenesis. The pilus itself is a helical structure comprised primarily of the major pilin, 
PilE. Five PilE subunits are arranged into three distinct layers of the pilus: a highly 
conserved core, a less-conserved central layer, and a hypervariable outer layer (Swanson 
1973; Schoolnik, Fernandez et al. 1984; So, Billyard et al. 1985). The structure of the 
pilus reveals a core made up of the N-terminus ends of the subunits, organized into a 
helix of overlapping α-helices. The amino terminal of pilE is highly conserved among 
different pilins (Schoolnik, Fernandez et al. 1984). Each pilin subunit has a 4-stranded 
antiparallel β-sheet and a sugar loop. The 4-stranded antiparallel β-sheet and sugar loop 
from each subunit are held together by hydrogen bonds to form a continuous β-sheet that 
makes up the central layer of the pilus fiber. The outermost region of the pilus has a β-
hairpin and the C-terminal tail. The outer layer is poorly conserved and is flexible to 
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allow for a large variety of amino acids, contributing to the antigenic variation among N. 
gonorrhoeae pilins (Forest and Tainer 1997). 
The pilus extends beyond the outer membrane, passing through the membrane 
protein PilQ (Figure 1.4) (Chen, Tobiason et al. 2004). Retraction of the pilus back 
through PilQ and into the cell contributes to the twitching motion seen among piliated 
gonococci. Expression of several proteins is involved in pilus formation and pilus-
associated functions (Meyer, Billyard et al. 1984; Drake and Koomey 1995; Wolfgang, 
Park et al. 1998; Wolfgang, van Putten et al. 2000; Helm, Barnhart et al. 2007). Among 
others, two ATPases, PilF and PilT are involved in pilus assembly and retraction, 
respectively (Freitag, Seifert et al. 1995; Wolfgang, Lauer et al. 1998; Forest, Satyshur et 
al. 2004). PilV is associated with adhesion to host epithelial cells (Winther-Larsen, 
Hegge et al. 2001) and PilD is involved with pilin processing and translocation to the 
membrane surface (Koomey, Bergstrom et al. 1991; Freitag, Seifert et al. 1995). 
Evidence suggests that tip of the pilus is composed of PilC, the pilus adhesion protein 
(Jonsson, Nyberg et al. 1991; Rudel, Scheurerpflug et al. 1995). 
PilE undergoes both phase and antigenic variation. Regions of silent loci, pilS, 
may be spontaneously recombined at the expression locus, pilE, allowing for the 
expression of antigenically variable pili (Meyer, Mlawer et al. 1982; Meyer, Billyard et 
al. 1984; Haas and Meyer 1986; Segal, Hagblom et al. 1986). The regions of pilS are 
donated to pilE in a non-reciprocal manner; thus the original pilS sequence does not 
change (Howell-Adams, Wainwright et al. 1996; Howell-Adams and Seifert 2000). 
Homologous recombination with DNA from other gonococcal cells also contributes to 
the variability among pilins (Serkin and Seifert 1998).These features allow for extreme 
 22 
 
variation among pili, such that almost all cells express a different pilus. Different 
sequences of pilE can be found in isolates from the same strain and different pilins are 
expressed by the gonococcus during the course of infection (Hagblom, Segal et al. 1985; 
Seifert, Wright et al. 1994). The pilus also undergoes phase variation. After 
approximately 24 hours of growth in vitro, piliated colonies shift to become non-piliated. 
A deletion in the expression site typically causes the P+ to P- shift (Segal, Billyard et al. 
1985; Seifert 1996)  
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Figure 1.3 Type IV pilus structure and formation 
The figure shows the basic structure of the N. gonorrhoeae type IV pilus. PilC is the 
adhesin located at the tip of the main pilus. The main pilus is made up of five units of 
PilE, which is translocated through the secretin PilQ. PilF and PilD are involved in pilin 
processing and formation while PilT is involved in pilin retraction. (Figure adapted from 
(Wolfgang, van Putten et al. 2000). 
 
 
  
PilC%
PilE%
PilQ%
PilD%
Disassembly/retrac3on%Assembly%
PilF%
Outer%membrane%
PilT%
Inner%membrane%
 24 
 
1.6.1.4 Porin 
Porins (PorB), which are water-filled channels that traverse the outer membrane 
of N. gonorrhoeae, are the most abundant protein in the outer membrane. This 
hydrophilic channel is a trimer of three identical subunits. Together, the subunits form a 
β-pleated-barrel structure. The barrel functions as a channel across the hydrophobic 
membrane, allowing the flow of ions and other small molecules between the bacterium 
and the environment (Young, Blake et al. 1983; Nikaido 1994; Achouak, Heulin et al. 
2001). PorB also contributes to the pathogenicity of N. gonorrhoeae (Blake and 
Gotschlich 1983). 
N. gonorrhoeae PorB can be found in one of two classes, PorB1A (PIA) or PorB1B 
(PIB) (Knapp, Tam et al. 1984). The alleles for both PIA and PIB are found at the same 
locus and each strain of N. gonorrhoeae expresses only one of the two subclasses, though 
PIA/PIB hybrids are possible (Gotschlich, Seiff et al. 1987; Carbonetti, Simnad et al. 
1988; Gill, Jayamohan et al. 1994; Cooke, Jolley et al. 1998). There are significant 
differences between PIA and PIB. The two classes have different orientations in the outer 
membrane. P1A is oriented such that a short portion of the N-terminus exposed to the 
environment, whereas the both termini of P1B are embedded in the outer membrane and 
the central portion is exposed to the extracellular environment (Judd 1989). Genetic 
variation is found among the exposed portions of both subclasses of PorB, a characteristic 
that is used in subtyping strains. 
Both forms of porin contribute to the pathogenicity of N. gonorrhoeae. PorB can 
translocate into the eukaryotic cell membrane, inhibit phagosome maturation, assist with 
bacterial entry into host cells, and down-regulate cell surface receptors necessary for 
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immune function (Lynch, Blake et al. 1984; Rudel, Schmid et al. 1996; Mosleh, Huber et 
al. 1998; van Putten, Duensing et al. 1998; Bauer, Rudel et al. 1999). 
Of the two subclasses of porin, PorB1A is more commonly found in disseminated 
gonococcal infections (Cannon, Buchanan et al. 1983). PIA is associated with mediating 
serum resistance, which the bacterium to escape normal human immune system responses 
(Ram, McQuillen et al. 1998; Ram, Cullinane et al. 2001). PIA is also better at 
facilitating host cell invasion than PIB (Garvin, Bash et al. 2008). PIB, on the other hand, 
is usually associated with localized infections and contributes to anti-microbial 
resistance. Isolates expressing PIB exhibit higher baseline resistance to antibiotics and 
mutations in this allele that contribute to antibiotic resistance have been described 
(Bygdeman, Mardh et al. 1984; Carbonetti, Simnad et al. 1990; Gill, Simjee et al. 1998; 
Olesky, Hobbs et al. 2002). 
 
1.6.1.5 Peptidoglycan 
N. gonorrhoeae has a thin layer of peptidoglycan separating the inner and outer 
membranes. The peptidoglycan layer of the cell represents < 2% of the total mass of the 
dry cell (Hebeler and Young 1976). Glycan chains are connected by short peptides to 
form a mesh-like structure that provides strength and support to the cell wall. Fragments 
of peptidoglycan released during cell wall synthesis are also linked to the pathogenesis of 
N. gonorrhoeae. The glycan chains are made up of alternating residues of N-acetyl 
glucosamine and N-acetylmuramic acid, which are connected by a β-(1,4) linkage. A 
peptide chain composed of L-Ala-D-γ-Glu-m-DAP-D-Ala-D-Ala is attached to each N-
acetylmuramic acid residue (Hebeler and Young 1976). Transpeptidation of the peptide 
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chains creates the cross-linked glycan chains with a ridged, strong structure. Penicillin-
binding proteins (PBPs) recognize the D-Ala-D-Ala end of the peptide chains and catalyze 
the release of the terminal D-Ala. (Ishino, Mitsui et al. 1980; Barbour 1981) The m-DAP 
on a neighboring peptide chain can then interact with the D -Ala to form a cross-link 
(Rosenthal, Wright et al. 1980). The glycan chains in N. gonorrhoeae range between 80-
110 disaccharides long (Hebeler and Young 1976).  
During cellular growth, fragments of peptidoglycan are released into the 
environment. Lytic transglycosylases cleave the bonds between the N-acetyl glucosamine 
and N-acetylmuramic acid residues and catalyze the formation of a 1,6-anhydro bond on 
the N-acteylmuramic acid (Rosenthal 1979; Cloud and Dillard 2002; Cloud-Hansen, 
Hackett et al. 2008). The peptidoglycan monomers that are released are cytotoxic to 
human cells, and the release of these monomers has been linked to fallopian cell damage 
and the processes of disseminated gonococcal infection (Melly, McGee et al. 1984; 
Cloud-Hansen, Hackett et al. 2008). 
 
1.7 Biology of infection 
1.7.1 Adherence to human cells 
Several of the structures mentioned above play an important role in N. 
gonorrhoeae attachment to human cells. Pili, Opa, LOS, and porin are all involved in the 
association between bacterial and human cells.  
Pili were implicated as adhesions in early pathogenesis studies. The pilus is 
necessary for the initial attachment to cells and the establishment of sustained infections 
(Punsalang and Sawyer 1973; Swanson 1973; McGee, Johnson et al. 1981; Merz and So 
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2000). Pili are important for attachment to host epithelial cells. PilC, located at the tip of 
the pilus, functions as an adhesin (Rudel, Scheurerpflug et al. 1995). Several studies have 
shown that CD46 (complement regulatory protein) serves as a receptor for the N. 
gonorrhoeae pilus to bind to the human cell (Kallstrom, Liszewski et al. 1997; Kallstrom, 
Blackmer Gill et al. 2001). However, there is also evidence of CD46-independent pilus 
binding (Kirchner, Heuer et al. 2005). In cervical epithelial cells, CR3 appears to be the 
primary receptor for the gonococcal pilus. Interestingly, the binding of pilus to CR3 is 
also dependent on porin (Edwards, Brown et al. 2002). During infection of the male 
urethra, the pilus binds to α1β1 or α2β1 integrins and the gonococcus-integrin complex 
next binds the asialoglycoprotein receptor (ASGP-R) on urethral epithelial cells (Edwards 
and Apicella 2005). Lipooligosaccharide then associates with the ASGP-R, creating a 
tight bond between the bacterium and the epithelium (Harvey, Porat et al. 2000; Harvey, 
Jennings et al. 2001).  
The gonococcal pilus might contribute to ascending infection of the upper female 
genital tract. Type IV pili are capable of causing a “twitching” motility (Merz, So et al. 
2000; Mattick 2002). This motility might aid the bacterium in ascending infection. In the 
upper female genital tract, the primary receptor for gonococcal adherence appears to be 
the lutropin receptor (LHr) along endometrial and fallopian tube epithelial cells (Spence, 
Chen et al. 1997). A gonococcal surface ribosomal protein, L12, mimics hCG, the normal 
human ligand for the LHr (Cruz, Anderson et al. 1987; Spence and Clark 2000; Ascoli, 
Fanelli et al. 2002). 
Opa proteins are also involved in binding to both epithelial cells and immune 
system cells. Opa proteins bind to one of two categories of receptors: carcinoembryonic 
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antigen cell adhesion molecules (CEACAMS) or heparin sulphate proteoglycans 
(HSPGs). Different types of CEACAMs are found on a variety of human cells. Epithelial 
cells express CEACAM1, CEACAM6, and CEACAM6 and Opa-CEACAM binding 
facilitates gonococcal adherence to epithelial cells (Wang, Gray-Owen et al. 1998; 
Sadarangani, Pollard et al. 2011). CEACAM3 is the primary CEACAM found on 
neutrophils, though CEACAM1 and CEACAM6 are also present at smaller levels. Opa-
CEACAM attachments on neutrophils are important for the bacterium to attach to the 
neutrophil, signaling downstream events related to invasion and killing (Chen and 
Gotschlich 1996; Gray-Owen, Dehio et al. 1997; Popp, Dehio et al. 1999; Chen, Bolland 
et al. 2001). Interactions between N. gonorrhoeae Opa and CEACAMs found on both T 
and B lymphocytes might also contribute to the pathogenicity of the bacterium by down-
regulating the immune response (Boulton and Gray-Owen 2002; Sadarangani, Pollard et 
al. 2011) 
While pili seem to provide the initial attachment to human cells, Opa interactions 
with receptors on the cells are necessary for internalization of the bacterium (Dehio, 
Gomez-Duarte et al. 1998). On epithelial cells, Opa-HSPG binding triggers transcytosis 
of the bacteria into the host cell (Grassme, Ireland et al. 1996; Grassme, Gulbins et al. 
1997). Opa attachment to CEACAMs on neutrophils can trigger phagocytosis of the 
bacterium and also stimulates the oxidative burst of the neutrophils (Gray-Owen, Dehio 
et al. 1997; Hauck, Meyer et al. 1998).  
Lipooligosaccharide molecules on the bacterial surface are also important for the 
initial attachment to host cells. As discussed earlier, the oligosaccharide units attached to 
the LOS core are highly variable. The structure of these chains can mimic human 
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glycosphingolipds, allowing the LOS molecules to bind host receptors that are meant to 
associate with the human glycosphingolipids (Harvey, Swords et al. 2001). Bacterial cells 
that do not express Opa utilize LOS to attach to host cells (Schneider, Cross et al. 1995; 
Song, Ma et al. 2000). On male urethral epithelial cells, LOS interactions with ASGP-R 
provide a tight connection between the bacterium and the host.  
 
1.7.2 Invasion of human cells and induction of the inflammatory response 
As discussed in section 1.7.1, several surface molecules of N. gonorrhoeae are 
involved with the initial attachment to host cells. These same molecules are also linked to 
host cell invasion by the bacterium. Pili and porin are necessary for the gonococcus to 
bind to CR3 on cervical epithelial cells. That interaction activates a signaling cascade, 
resulting in ruffling of the epithelial cell to engulf the bacterium (Griffiss, Lammel et al. 
1999; Merz, Enns et al. 1999). In the cells of the upper female genital tract, attachment of 
the bacteria to non-ciliated epithelium promotes sloughing of the nearby ciliated 
epithelial cells (McGee, Stephens et al. 1983; Stephens, McGee et al. 1987). Trancytosis 
through the non-ciliated epithelial cell, as well as the sloughing of the ciliated epithelium, 
provide the bacterial cells with access to subepithelial tissues (McGee, Stephens et al. 
1983).  
The inflammatory response to gonococcal infections results from interactions 
between bacterial virulence factors and host cells. Nearly all men with gonorrhea are 
symptomatic, due to the influx of neutrophils and the release of inflammatory cytokines 
near the urethral epithelium. LOS causes urethral epithelial cells to secrete TNF-α, IL-1β, 
IL-6, and IL-8 (Ramsey, Schneider et al. 1995; Harvey, Post et al. 2002). These 
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chemokines cause a large influx of neutrophils, resulting in the purulent discharge seen 
clinically. Porin is able to insert into the membrane of the phagocyte, inhibiting 
degranulation and the oxidative burst. This allows bacterial cells to survive within 
phagocytes. In women, gonococci are taken up by epithelial cells in the lower genital 
tract because of interactions with CR3 and CEACAMs. The bacteria trigger signaling 
events that promote uptake into epithelial cells and also produce a favorable environment 
within the host cell. Interestingly, this does not promote an inflammatory response, 
explaining the lack of symptoms in most females (Hedges, Mayo et al. 1999). N. 
gonorrhoeae also inhibits complement activity in women, contributing to the bacterium’s 
ability to survive in the host (Edwards and Apicella 2004) The bacterium then is able to 
access sub-epithelial tissue and also proceed up the genital tract to cause the 
complications such as PID. 
The gonococcus causes the most damage in the upper female genital tract. The 
lutropin receptors (LHr) that serve as receptors for gonococcal attachment in the 
endometrium and fallopian tubes are also found on the uterus, placenta, decidua, and fetal 
membranes (Reshef, Lei et al. 1990). Infection with gonorrhea increases the risk of 
spontaneous abortion, perhaps through attachment to these receptors. Gonococcal porin 
can translocate into eukaryotic cell membranes where it induces apoptosis. This is 
believed to be a factor in upper female genital tract infection, contributing to the 
cytotoxicity of the organism. Growing gonococcal cells release peptidoglycan monomers 
into the host environment. These monomers have been shown to be cytotoxic to fallopian 
tube cells (Melly, McGee et al. 1984; Cloud and Dillard 2002). Gonococcal LOS and pili 
are also toxic to the cells of the upper female genital tract (Johnson, Taylor-Robinson et 
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al. 1977; Gregg, Johnson et al. 1981; Gregg, Melly et al. 1981; Stephens, McGee et al. 
1987; Velasquez, Garcia et al. 2012). 
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Figure 1.4 Infection of male urethral epithelial cells and the inflammatory response  
The initial attachment between the epithelial cells of the male urethra and the gonococcus 
is through the pilus. Next, the gonococcal LOS binds to the asialoglycoprotein receptor 
on urethral epithelial cells, creating a tight association between the bacterium and the 
epithelium. The bacterial LOS elicits cytokine production by infected epithelial cells, 
causing an influx of PMNS and ultimately resulting in the symptoms seen in nearly all 
men with gonorrhea. (Figure adapted from (Edwards and Apicella 2004)) 
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1.7.3 Serum Resistance 
N. gonorrhoeae is able to evade normal human immune system responses. 
Antigenic and phase variation and the endless ability to modify surface structures allows 
the bacterium to easily escape recognition by the host. Gonococci are able to cause 
disseminated infection because the species has developed defenses against the 
complement cascade responsible for killing bacterial cells. Porin plays a large role in this 
serum resistance. PIA can bind Factor H, inhibiting the induction of the alternative 
complement pathway (Ram, McQuillen et al. 1998; Ram, Sharma et al. 1998). PIA can 
also bind to C4b-binding protein, inhibiting the classical complement pathway (Ram, 
Cullinane et al. 2001; Ram, Cullinane et al. 2001b). Sialylation of LOS allows the 
lipooligosaccharide to bind to Factor H or C4b (Ram, Sharma et al. 1998; Ram, Cox et al. 
2003). These interactions cause a decrease in both the classical and alternative 
complement pathways.  
 
1.7.4 Defenses against oxidative killing 
N. gonorrhoeae encounters several sources of oxidative stress during infection of 
human hosts. Defenses against oxidative stress promote survival and thus increase the 
virulence of the organism. We propose that oxidative stress defenses might even play a 
role in antibiotic resistance (Chapter 4).  Sources of oxidants are varied and include the 
by-products of the bacterium’s own metabolic processes, oxidative products released 
after the host inflammatory response, and products of metabolic processes of commensal 
bacteria (Naids and Rest 1991; Zheng, Alcorn et al. 1994; Criss and Seifert 2008). 
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Oxidants have the potential to kill the gonococcus by damaging interactions with DNA, 
RNA, cellular membranes, and proteins (Imlay 2003). 
The gonococcus has developed many mechanisms to defend itself against 
oxidative stress. The response to hydrogen peroxide (H2O2) has been studied extensively 
in the attempts to characterize oxidative defense pathways in N. gonorrhoeae. Microarray 
analysis showed changes in the levels of transcription of over 150 genes (Stohl, Criss et 
al. 2005). The OxyR regulon, consisting of gor, prx, and katA, is important for defenses 
against H2O2. Catalase converts harmful H2O2to oxygen and water. Catalase (katA) 
mutants are more sensitive to both H2O2and paraquat and the presence of katA increases 
resistance to in vitro killing and DNA damage from human PMNs and commensal 
bacteria (Zheng, Alcorn et al. 1994; Soler-Garcia and Jerse 2004). 
A significant amount of superoxide (O2−) can be formed during aerobic 
respiration in N. gonorrhoeae. Under normal conditions, bacterial defenses are able to 
convert the O2− into hydrogen peroxide, which is then managed by the peroxide defenses 
mentioned above. While superoxide dismutases (SOD) are important for detoxifying O2− 
in other bacterial species, the manganese ion (Mn2+) appears to play a major role in 
protecting against O2−  killing by quenching the toxic radicals (Tseng, Srikhanta et al. 
2001). Though Mn2+ and manganese transporter are the major mechanisms for protecting 
N. gonorrhoeae from superoxide, low levels of SodB also contribute (Stohl, Criss et al. 
2005).  
N. gonorrhoeae is exposed to other reactive oxygen and nitrogen species (ROS 
and RNS) throughout the course of human infections. The pathogen has developed 
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complicated mechanisms involving many genes and pathways to avoid cellular damage 
and death caused by these toxic radicals.  
1.8 Natural Transformation and Competence of N. gonorrhoeae 
N. gonorrhoeae is remarkable in its ability to take up exogenous DNA from the 
environment and incorporate that DNA into its own chromosome, provided that it has 
≥85% identity with DNA it replaces. This natural competence has allowed the gonococci 
to use transformation to acquire new genetic material. Proposed reasons for the uptake of 
DNA include the use of DNA as a nutritional source, aid in the repair of damaged 
chromosomes, acquisition of new virulence factors, and generation and spread of genetic 
diversity (Sparling 1966; Hobbs, Seiler et al. 1994). The gonococcus uses natural 
transformation as its only mechanism for mobilizing chromosomal loci and as its main 
mechanism of horizontal gene exchange (Sox, Mohammed et al. 1978; Koomey 1998). N. 
gonorrhoeae is one of approximately 70 bacterial species that are recognized as naturally 
competent (Johnsborg, Eldholm et al. 2007). 
 
1.8.1 Natural competence of the gonococcus 
Unlike most other naturally competent species, N. gonorrhoeae is nearly always 
competent; most other species regulate the expression of the proteins required for 
competence based on cellular needs or environmental signals. The competence genes of 
the gonococcus are constitutively expressed, a fact that is supported by the fairly easy 
ability to naturally transform the species in the laboratory. Gonococci have been reported 
to be highly competent during all phases of growth (Sparling 1966; Biswas, Sox et al. 
1977). The presence of a ten base-pair uptake sequence (US) (5’-GCCGTCTGAA-3’) is 
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required for the gonococci to take up DNA (Graves, Biswas et al. 1982; Goodman and 
Scocca 1988; Elkins, Thomas et al. 1991). This US is found approximately every 1000 
base pairs in N. gonorrhoeae and is also found frequently in N. meningiditis and the 
commensal Neisseria species. Recent studies have shown that uptake of non-US 
containing DNA is possible and that the efficiency of this process is highly strain 
dependent (Duffin and Seifert 2010). 
 
1.8.2 Sources of DNA for transformation 
Since N. gonorrhoeae primarily takes up DNA with the Neisseria-specific US, the 
source of genetic material for transformation is most often a co-infecting N. gonorrhoeae 
strain in the human host; the exchange of chromosomal DNA during mixed infections is 
common (Hamilton and Dillard 2006). However, transformation is also possible between 
N. gonorrhoeae and other Neisseria species, such as the pathogenic species N. 
meningiditis or commensal species such as N. cinerea, N. flavescens, N. sicca, and N. 
lactamica, among others. In fact, transfer from commensal species was responsible for 
the creation of the allele that codes for a mutated penicillin binding protein that 
contributes to penicillin resistance in N. gonorrhoeae (Spratt, Zhang et al. 1989; Spratt, 
Bowler et al. 1992).  
Donor cells release DNA for transformation either through a type IV secretion 
system (T4SS) or through autolysis of the donor cell. Nearly 80% N. gonorrhoeae strains 
possess the gonococcal genetic island (GGI), which encodes a T4SS (Dillard and Seifert 
2001). Genes of the GGI allow for the secretion of single stranded DNA into culture 
medium (Hamilton, Schwartz et al. 2001; Hamilton, Dominguez et al. 2005; Ito, Deguchi 
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et al. 2005). Gonococci can take up the DNA secreted by the T4SS and recombine it into 
their own chromosomes. This method allows for survival of the donor cell. Strains that do 
not carry a GGI must use autolysis as the source of genetic material for transformation. 
Autolysis occurs frequently in culture systems; cells are prone to autolysis during 
stationary phase or when exposed to non-ideal growth conditions (Morse and Bartenstein 
1974; Hebeler and Young 1975; Elmros, Burman et al. 1976; Elmros, Sandstrom et al. 
1976). In vivo, autolysis is probably mediated by amidases that break down 
peptidoglycan in the cell wall (Hebeler and Young 1976). Autolysis can also occur due to 
instability of the outer membrane (Cacciapuoti, Wegener et al. 1978; Bos, Tefsen et al. 
2005). It has been shown that DNA released upon autolysis can be used for 
transformation (Norlander, Davies et al. 1979). 
 
1.8.3 DNA binding and uptake 
After DNA is released (either through a T4SS or through autolysis), the recipient 
cell must recognize and bind the DNA. DNA uptake and transport into the cell is separate 
from the initial binding of DNA to the cell surface. Binding and uptake are dependent on 
a variety of proteins. Piliated gonococci have a much higher transformation frequency 
than their non-piliated counterparts, indicating that there is a role in transformation for at 
least some of the genes involved in Tfp biogenesis and expression (Biswas, Sox et al. 
1977). Opa proteins and ComP, a minor pilus protein, assist with dsDNA binding to the 
cell surface (Hill 2000; Aas, Lovold et al. 2002; Aas, Wolfgang et al. 2002). The Tfp is 
clearly involved in non-specific DNA binding, though a fully functional pilus is not 
necessary for DNA uptake (Boyle-Vavra and Seifert 1996; Zhao, Tobiason et al. 2005). 
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Mutations in pilC, pilE, pilF, and pilG have all been linked to a reduction in 
transformation efficiency (Rudel, Facius et al. 1995). PilQ, the pore through which the 
pilus is extruded, and other components of the secretin complex, such as PilM, PilN, 
PilO, and PilP, are required for transformation, since mutations in any of these proteins 
completely ablates transformation (Zhao, Tobiason et al. 2005). The pilus like protein 
ComP and PilV both affect binding of DUS containing DNA. ComE, found in the 
periplasm, binds DNA non-specifically and is believed to be important for DNA uptake 
once the DNA is has crossed the outer membrane (Chen and Gotschlich 2001). ComL, a 
lipoprotein, assists with creating an opening in the peptidoglycan layer for DNA entry 
(Fussenegger, Facius et al. 1996). ComA is found on the inner membrane and most likely 
assists with DNA transport from the periplasm to the cytoplasm (Facius and Meyer 
1993). PilT, the NTPase necessary for retraction of the Tfp, is necessary for pulling the 
DNA, bound to the pilus or pilus-like apparatus, into the cell (Wolfgang, Lauer et al. 
1998; Aas, Wolfgang et al. 2002). 
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Figure 1.5 DNA uptake and binding for transformation by N. gonorrhoeae 
DNA binding and uptake requires the expression of several proteins. The pilus adhesion 
protein, PilC, and the major pilus protein, PilE, as well as the minor pilin protein PilV are 
involved. The secretin PilQ, the secretin complex proteins PilM, PilN, PilO, and PilP, and 
the pilus retraction protein PilT are also necessary. Pilus biogenesis proteins PilD, PilF, 
and PilG are necessary even though a fully functional pilus is not required for 
transformation. ComP, ComL, ComE, ComA, and Tpc also play roles in the DNA uptake 
process. (Figure adapted from (Hamilton and Dillard 2006).) 
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1.8.4 DNA processing 
Gonococci can be transformed with either plasmid or chromosomal DNA, but 
transformation with chromosomal DNA is much more efficient (Eisenstein, Sox et al. 
1977). Large plasmids are processed into linear dsDNA and are subject to restriction by 
endonucleases in the gonococcus (Stein, Gunn et al. 1995). Chromosomal DNA is not 
subject to the same restriction systems as plasmid DNA, perhaps because endonucleases 
do not act on ssDNA. Both dsDNA and ssDNA are subject to uptake by N. gonorrhoeae, 
but evidence shows that dsDNA is converted to ssDNA in the periplasm, which would be 
resistant to restriction modification systems (Biswas and Sparling 1981; Chaussee and 
Hill 1998). 
 
1.8.5 Homologous recombination into the chromosome 
Homologous recombination is the next step in natural transformation, but it is also 
involved with other processes in N. gonorrhoeae. In addition to using homologous 
recombination to incorporate exogenous DNA into its chromosome, the bacterium also 
uses homologous recombination to repair DNA damage and create antigenic diversity 
among pilins. The recombination pathways used for natural transformation, pilin 
angtigenic variation, and DNA repair are not fully understood and require different 
proteins (summarized in Table 1.2). Homologous recombination is dependent on RecA in 
N. gonorrhoeae, with RecA mutants showing a complete lack of transformation (Koomey 
and Falkow 1987; Koomey, Gotschlich et al. 1987). Other proteins involved in 
recombination include PriA, RecBCD, Rep, RecX, and RecN (Mehr and Seifert 1998; 
Stohl and Seifert 2001; Kline and Seifert 2005; Kline and Seifert 2005). In E. coli, the 
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RecBCD pathway is used to repair double stranded DNA breaks and the RecF pathway is 
used to repair single stranded breaks. Interestingly, RecX inhibits RecA mediated 
activities in E. coli, but enhances homologous recombination (mediated through RecA) in 
N. gonorrhoeae, indicating that though there are some similarities, the recombination 
pathways of these two bacteria are quite different (Gruenig, Stohl et al. 2010). While no 
RecF homologue has been identified in the gonococcus, genes encoding RecQ and RecO 
(both of which are involved in the E. coli RecF pathway) are present and are involved in 
homologous recombination in N. gonorrhoeae, but are not necessary for natural DNA 
transformation (Mehr and Seifert 1998). This RecF-like pathway in N. gonorrhoeae has 
instead been linked to homologous recombination events involved in pilin antigenic 
variation. RecJ has been characterized as an exonuclease involved in homologous 
recombination events necessary for pilin variation and DNA repair (Skaar, Lazio et al. 
2002), while PriA is important for transformation events but is not necessary for pilin 
antigenic variation. RecN is also involved in recombination involved with transformation, 
but the exact mechanism is unknown. Rep, a helicase, is necessary for both 
transformation and antigenic variation, but is not linked to DNA repair events (Kline and 
Seifert 2005). Gonococci with a RecBCD-mutation have decreased transformation 
efficiency, but are still capable of intermediate-level transformation frequencies. Thus, a 
third recombination pathway, unrelated to RecBCD or the RecF-like pathway, is likely 
present in N. gonorrhoeae. It has been proposed that dsDNA utilizes the RecBCD 
pathway, while ssDNA utilizes a separate, as yet unidentified, mechanism. It is clear that 
the complex mechanisms involved in homologous recombination pathways in N. 
gonorrhoeae are not fully understood.  
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Table 1.2 Genes Involved in Homologous Recombination Processes in N. 
gonorrhoeae 
N. gonorrhoeae uses homologous recombination for natural transformation, DNA repair, 
and pilin antigenic varation. While the pathways are not fully elucidated, some genes 
have been identified for each of the three processes. The “X” in the table below indicates 
that a gene is involved in the pathway. 
 
 
 Natural 
Transformation 
DNA Repair Pilin Antigenic 
Variation 
priA X X  
recA X X X 
recBCD X X  
recJ  X X 
recN X X  
recO  X X 
recQ  X X 
recX X X X 
rep X  X 
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1.9 Antibiotic resistance in N. gonorrhoeae 
The emergence of resistance to nearly all major classes of antimicrobials makes 
gonorrhea increasingly difficult to treat (Figure 1.7). In the 1930’s, the sulfonamides 
were introduced and used to successfully treat infections with N. gonorrhoeae. However, 
by the mid 1940’s, resistance to sulfonamides made the drugs useless against gonococcal 
infections. Sulfonamides were no longer recommended for the treatment of GC infections 
by 1949. Around the same time (the mid-1940’s), penicillin was introduced as the drug of 
choice for gonorrhea infections. Early gonococcal isolates had a Minimum Inhibitory 
Concentration (MIC) of 0.004-0.01 μg/mL for penicillin and were thus extremely 
sensitive to the antimicrobial. In 1958, strains of N. gonorrhoeae with decreased 
susceptibility to both penicillin and streptomycin were reported (Cradock-Watson, 
Shooter et al. 1958). Over the next 40 years, the MICs of penicillin slowly increased, 
such that by the late 1970’s and early 1980’s the MICs of penicillin for some strains were 
greater than 2 μg/mL, indicating resistance to the antibiotic. By 1987, treatment failure 
with penicillin was widespread and the drug was no longer recommended for the 
treatment of GC infections. Also in the 1980’s, increasing MICs of tetracycline became 
widespread, eventually leading to resistance and the withdrawl of tetracycline as a 
recommended treatment by option by the CDC. In the 1996, fluoroquinolones were 
introduced as a treatment for gonorrhea; however, resistance to this class of antibiotics 
began to develop soon after, and by 2007, the CDC stopped recommending the use of 
fluoroquinolones to treat GC infections because of the development of widespread 
resistance and treatment failure (Centers for Disease Control and Prevention 
2007)(Centers for Disease Control and Prevention 2007)(Centers for Disease Control and 
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Prevention 2007)(Centers for Disease Control and Prevention 2007)(Centers for Disease 
Control and Prevention 2007)(Centers for Disease Control and Prevention 2007)(Centers 
for Disease Control and Prevention 2007). In the same year, the CDC added N. 
gonorrhoeae to its list of “superbugs”, highlighting the difficulty in treating gonorrhea 
infections with resistance to beta-lactams, spectinomycin, tetracycline, azithromycin, and 
fluoroquinolones. The expanded-spectrum cephalosporins, cefixime and ceftriaxone, are 
currently the only antibiotics recommended against N. gonorrhoeae, but unfortunately 
resistance to these antibiotics is also increasing. As shown in Figure 1.7, the percentage 
of gonococcal strains with decreased susceptibility to ceftriaxone in Japan increased 
dramatically from 2001 to 2007. In 2009, reports of treatment failure with ceftriaxone 
and cefabuten began to emerge in the treatment of pharyngeal gonorrhea (Tapsall, Read 
et al. 2009). In 2010, a N. gonorrhoeae strain isolated in Japan was reported to have 
MICs of 2 μg/mL for ceftriaxone and 8 μg/mL with cefixime, and in 2011, a strain with 
MICs of 2 and 8 μg/mL for ceftriaxone and cefixime was isolated in France from a man 
who has sex with men (MSM) after he underwent treatment failure with cefixime 
(Ohnishi, Golparian et al. 2011; Unemo, Golparian et al. 2012). Both of these strains 
have MICs that are well beyond the levels considered as susceptible for these antibiotics 
(the resistance breakpoint is 0.25 μg/mL for both ceftriaxone and cefixime). 
The Gonococcal Isolate Survelliance Project (GISP) reports data concerning 
antimicrobial susceptibility among gonococcal isolates collected in the United States each 
year. The most recent report found that 27.2% of isolates collected in 2010 were resistant 
to penicillin, tetracycline, ciprofloxacin, or a combination of those drugs. An increase in 
isolates with decreased susceptibility to azithromycin and cefixime, cefpodoxime, and 
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ceftriaxone was also observed. (Centers for Disease Control and Prevention 2011). While 
the United States has not yet reported the high-levels of resistance to the broad-spectrum 
beta-lactams that have been reported in Asia and Europe, susceptibility to these drugs is 
clearly decreasing and it is only a matter of time before they will no longer be useful for 
treatment of gonococcal infections. 
Multiple labs, including ours, have explored the mechanisms by which N. 
gonorrhoeae becomes resistant to antimicrobials. Resistance to antibiotics can be either  
plasmid-mediated or chromosomally mediated. Plasmid-mediated resistance is observed 
for penicillin (expression of a β-lactamase) and tetracycline (production of TetM, a 
protective protein that prevents tetracycline action). For chromosomally mediated 
resistance, mechanisms include alterations of the drug target, modification of the drug, 
changes in permeability of the cell, and efflux of the drug out of the cell. N. gonorrhoeae 
has utilized all of these mechanisms. Table 1.3 summarizes some of the antimicrobial 
resistance mechanisms utilized by N. gonorrhoeae. 
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Table 1.3 Mechanisms of antibiotic resistance 
Bacteria employ several different mechanisms to avoid killing by antibiotics. Some of 
these are intrinsic while others are acquired. The mechanisms can be broken down into 
four main categories shown in this table.   
 
Mechanism Description Examples Intrinsic or 
Acquired 
Decrease in 
permeation 
across the outer 
membrane 
Outer membrane gives 
intrinsic resistance by 
limiting entry to 
bacterium. Mutations 
altering permeability 
increase resistance 
significantly. 
penB-Mutation in porB1b 
Increases resistance to penicillin, 
third generation cephalosporins 
and tetracycline. 
penC-mutation in pilQ reducing 
entry of penicillin and 
tetracycline (Zhao, Tobiason et 
al. 2005). 
Both 
Drug 
Modification 
Bacteria can produce 
enzymes that alter 
antibiotics, resulting in 
decreased efficacy or 
complete uselessness of 
the antibiotic. 
β-lactamases-Some strains of N. 
gonorrhoeae harbor plasmids 
that code for β-lactamases, 
which are enzymes that 
hydrolyze the β-lactam ring of 
penicillin and other β-lactam 
antibiotics (Ashford, Golash et 
al. 1976). 
Acquired 
Target 
Modification 
Antibiotics work to kill 
bacteria through several 
different pathways. 
Bacteria have developed 
mechanisms to alter 
drug targets to escape 
killing by different 
antibiotics and these 
altered targets have 
spread throughout 
bacterial populations. 
penA-Mutations in PBP2 that 
result in a decreased rate of 
acylation by penicillin were first 
described in 1974 (Sarubbi, 
Blackman et al. 1974). 
rpsJ-Mutation in the ribosomal 
protein S10 that results in high 
level tetracycline resistance (Hu, 
Nandi et al. 2005). 
gyrA and parC-Mutations in 
DNA gyrase and topoisomerase 
IV that cause resistance to 
fluoroquinolones (Belland, 
Morrison et al. 1994). 
Acquired 
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Drug Efflux Bacteria have several 
types of efflux pumps 
that function to remove 
antibiotics and waste 
products from the cell. 
These give a baseline 
level of resistance to the 
cell. Mutations have 
been identified that 
increase expression, 
thereby conferring 
increased resistance to 
various antibiotics. 
MacAB-A promoter mutation 
has been identified that increases 
resistance to macrolides 
(Rouquette-Loughlin, Balthazar 
et al. 2005). 
MtrCDE-Mutations in the mtr 
(multiple transferable resistance) 
locus confer resistance to a wide 
range of antimicrobials (Maness 
and Sparling 1973). These 
mutations result in 
overexpression of the efflux 
pump. 
Both 
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Figure 1.6 Timeline of antibiotics used in the treatment of N. gonorrhoeae infections 
Since the introduction of the sulfonamides for the treatment of gonococcal infections in 1938, the bacterium has developed 
resistance to every class of drugs used to treat gonorrhea. Figure adapted from (Unemo and Shafer 2011). 
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Figure 1.7 Increasing resistance to ceftriaxone in N. gonorrhoeae 
The percentage of strains in Japan with decreased susceptibility to ceftriaxone increased 
dramatically from 2001 to 2007 (M. Ohnishi, personal communication). 
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1.9.1 Plasmid mediated resistance to penicillin and tetracycline 
In 1976, two different types of beta-lactamase encoding plasmids were reported in 
Africa and Asia (Ashford, Golash et al. 1976; Phillips 1976). Since then, other plasmids 
encoding the β-lactamase enzyme TEM-1 have also been discovered (Dillon and Yeung 
1989). Penicillin and other β-lactam antibiotics exert their antibacterial effects by 
interfering with cell wall synthesis in the bacteria. The antibiotic binds to the enzymes 
responsible for the cross-linking of the peptidoglycan layer that surrounds the cell and 
confers rigidity and viability to the bacterium. Disruption of a proper peptidoglycan layer 
results in bacterial cell death. Plasmid-mediated penicillin resistance involves the 
production of a TEM-1 β-lactamase, which hydrolyzes and inactivates the antibiotic. The 
gonococcal β-lactamase plasmid most likely was acquired from Haemophilus ducreyi 
(Anderson, Albritton et al. 1984). 
Tetracycline binds to the 30S subunit of the bacterial ribosomes and inhibits 
protein synthesis by blocking the aminoacyl-tRNA from binding to the A site of the 
ribosome. Plasmid-mediated tetracycline resistance is caused by the TetM  determinant, 
which encodes for a protein that protects to ribosome from tetracycline. The tetM gene is 
carried on a large conjugative plasmid that was originally found in bacteria from the 
Streptococcus genus and is also found in Mycoplasma hominis, Ureaplasma urealyticum, 
and Gardnerella vaginalis, which are pathogens that colonize the urogenital tract (Morse, 
Johnson et al. 1986). The plasmid is easily transferred between N. gonorrhoeae strains. 
The conjugative plasmid also mobilizes the β-lactamase plasmids, contributing to the 
spread of penicillin and tetracycline resistance. High-level plasmid-mediated tetracycline 
resistance was first identified in 1982 and within three years, strains harboring the tetM 
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plasmid were widespread throughout North American and Europe. Two variants of the 
tetracycline resistance plasmid have been identified, one is believed to have originated in 
the Far East and the other is most likely of African origin (Turner, Gough et al. 1999). 
 
1.9.2 Chromosomally mediated resistance 
Chromosomally mediated resistance involves the horizontal transfer of resistance 
determinants. Step-wise transfer of resistance genes occurs from a resistant strain to a 
sensitive strain through DNA uptake and homologous recombination (Cannon and 
Sparling 1984). Because N. gonorrhoeae is a naturally competent organism, 
chromosomally mediated resistance has been an efficient mechanism of spreading 
antibiotic resistance and is much more common than plasmid-mediated resistance. 
Approximately 12% of circulating gonococcal strains exhibit chromosomally mediated 
penicillin resistance, while only 1% of strains exhibit plasmid-mediated penicillin 
resistance (Centers for Disease Control and Prevention 2011). Chromosomally mediated 
resistance is more complex than plasmid-mediated resistance and involves the transfer of 
several genes. 
 
1.9.2.1 Chromosomally mediated penicillin resistance 
Chromosomally mediated resistance to penicillin involves the transfer of several 
genes in a specific order. Each of the genes individually increases resistance 
incrementally (2- to 5-fold), but when combined together, they result in a nearly 400-fold 
increase in the MIC of penicillin (Figure1.8). At least five genes are involved in 
chromosomally mediated penicillin resistance (Table 1.4). The first four determinants can 
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be transferred from penicillin-resistant strains to penicillin-sensitive strains in the 
laboratory, but transformation to high-level resistance equal to that of the donor strains 
has not yet been achieved. 
The step-wise transfer of chromosomally mediated resistance begins with the 
transfer of a mutated penA gene, which encodes a mutated form of penicillin-binding 
protein 2 (PBP2), the essential PBP that catalyzes the transpeptidase reactions necessary 
cross-linking the peptidoglygan during cell wall synthesis. Mutations in penA likely were 
acquired by horizontal transfer from a commensal Neisseria species, N. flavescens 
(Spratt, Zhang et al. 1989). Altered PBP2 variants have a lower acylation rate with 
penicillin, resulting in a 4-6-fold increase in the MIC of the antibiotic. The most 
commonly mutated form of PBP2 from penicillin-resistant strains differs from wild type 
by an insertion of an aspartate at position 345a and 4-8 mutations in the C-terminal tail.  
The second resistance determinant is a mutation in the mtr (multiple transferable 
resistance) locus. This mutation was described in 1973 as a mutation in the outer 
membrane that caused increased resistance to a wide variety of antimicrobials (Maness 
and Sparling 1973; Guymon and Sparling 1975; Guymon, Walstad et al. 1978). Later, it 
was discovered that the mutation actually caused an increase in drug efflux out of the 
bacterial cell because of increased activity of an efflux pump (Pan and Spratt 1994; 
Hagman, Pan et al. 1995). Overexpression of the MtrC-MtrD-MtrE efflux pump results 
from a single base pair deletion in the regulatory region of the gene (Hagman and Shafer 
1995). This deletion increases transcription and relieves the repression caused by the 
MtrR repressor. The MtrR repressor binds and represses the transcription of the MtrC-
MtrD-MtrE efflux pump (Lucas, Balthazar et al. 1997). MtrC, mtrD, and mtrE are 
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transcribed as a single transcriptional unit and are opposite from the regulatory mtrR, 
with the promoters of mtrCDE and mtrR overlapping. With the mtrR mutation, the 
spacing between the -10 and -35 regions of the MtrC-MtrD-MtrE promoter is disturbed, 
resulting in decreased binding of the repressor. While the most common mutation is this 
single base-pair deletion, other clinically relevant mutations that also result in the de-
repression of the efflux pump also been described (Zarantonelli, Borthagaray et al. 2001; 
Cousin, Whittington et al. 2003; Cousin, Roberts et al. 2004). Overexpression of the 
efflux pump increases non-specific antimicrobial resistance by pumping antimicrobials 
out of the cell and by activating porin mutations (see below) that limit antimicrobial 
influx into the cell.  
The third resistance determinant, termed penB, encodes a mutant form of the outer 
membrane protein porin, PorB1B (porB1B). Alterations in loop 3, which folds into the 
barrel and constricts the pore, decrease diffusion of antibiotics across the outer membrane 
of N. gonorrhoeae (Gill, Simjee et al. 1998; Olesky, Hobbs et al. 2002). Surprisingly, 
penB mutations are phenotypically silent in the absence of a co-resident mtrR mutation, 
suggesting a complex interaction between the two determinants (Olesky, Zhao et al. 
2006). It is also important to note that penB mutations only appear in gonococcal strains 
expressing the PorB1B allele, but do not appear in strains with the PorB1A allele.  
The fourth resistance determinant, ponA, encodes for an altered form of PBP1. 
The altered form has a lower rate of acylation for penicillin (Ropp, Hu et al. 2002). 
Surprisingly, the ponA determinant does not increase resistance when transformed into a 
3rd level transformant (e.g. FA19 penA mtrR penB), but resistance decreases 2-fold when 
the ponA determinant is replaced with the wild-type ponA allele. A fifth resistance 
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determinant, which we call Factor X, is an unknown determinant that is required for 
high-level penicillin resistance. Unlike the other determinants, Factor X is not 
transformable in the laboratory, making its identification and characterization difficult.  
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Figure 1.8 Genetics of penicillin resistance 
MICs of FA19 with known resistance determinants are shown. Each determinant only 
increases resistance incrementally, but when combined, there is almost a 400-fold 
increase in resistance between the susceptible strain (FA19) and the resistant strain 
(FA6140) (Maness and Sparling 1973; Sarubbi and Sparling 1974; Olesky, Hobbs et al. 
2002). 
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Table 1.4 Resistance determinants involved in chromosomally mediated 
penicillin resistance in N. gonorrhoeae 
At least five genes are involved in high-level resistance to penicillin. The genes and 
their functions are listed. 
 
Resistance 
Determinant Protein encoded / Mechanism 
penA PBP 2/Altered forms that have a decreased acylation rate with β-lactam antibiotics 
mtrR 
---/Promoter mutation that increases transcription of the MtrC-MtrD-MtrE 
efflux pump that pumps hydrophobic agents and antibiotics out of the 
cell 
penB 
PorB1b/Mutations in PorB1b porin at positions G120 and A121 in loop 3, 
which folds into the barrel and constricts the pore; requires the presence of 
the mtrR mutation for phenotype 
ponA PBP 1/Altered form that has a decreased affinity for β-lactam antibiotics 
Factor X ---/Unknown determinant(s) that is(are) required for high-level (MIC ≥ 2 μg/ml) penicillin resistance 
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1.9.2.2 Chromosomally mediated tetracycline resistance 
Chromosomally mediated resistance to tetracycline has been well characterized in 
N. gonorrhoeae. As with penicillin resistance, the acquisition of several genes is 
necessary for full resistance. In addition to their roles in penicillin resistance, mutations 
in mtrR and penB are also involved with resistance to tetracycline (Sparling, Sarubbi et 
al. 1975). A third determinant, rpsJ1, encodes for a mutation in the ribosomal binding 
protein S10 (Hu, Nandi et al. 2005). This mutation is necessary for high-level tetracycline 
resistance and likely disrupts the binding of tetracycline to the 30S subunit of the 
bacterial ribosome. 
 
1.10 N. gonorrhoeae vaccine attempts 
Because of the development of resistance to nearly all classes of antimicrobials, 
several groups have tried to develop a vaccine against N. gonorrhoeae. In fact, “vaccine 
therapy” was used even before antibiotics were available. Early vaccine attempts were 
simply whole cell lysates that were injected into joints (Stockman 1911). Surface 
structures are the obvious vaccine targets, but the ability of N. gonorrhoeae to quickly 
modify those structures makes vaccine design difficult. Additional complications exist 
because the gonococcus is able to suppress both CD4(+) T cell and B cell responses 
(Boulton and Gray-Owen 2002; Pantelic, Kim et al. 2005). Vaccines against the 
gonococcal pilus have been designed and did elicit an immune response, but are not 
effective because of the vast degree in variability among pilins (Schoolnik, Tai et al. 
1983). No protection was provided from an experimental pilus vaccine given to members 
of the US military, likely because of antigenic variation among the pili (Anonymous 
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1983; Boslego, Tramont et al. 1991). Vaccines against the Opa proteins are also 
problematic due to variability in expression among, and within, strains (Hobbs, Seiler et 
al. 1994; Jerse, Cohen et al. 1994; Plummer, Chubb et al. 1994). While there is also much 
variability in LOS, studies show that conserved regions may be used as vaccine targets 
(Gulati, McQuillen et al. 1996; Gulati, McQuillen et al. 1996; Yamasaki, Koshino et al. 
1999; Ngampasutadol, Rice et al. 2006). Studies utilizing porin as a vaccine target are 
underway since it is more antigentically stable than some of the other outer membrane 
structures (Wetzler, Blake et al. 1992; Zhu, Thomas et al. 2004; Wetzler 2010). A 
combination of a gonococcal antigen with a viral-like particle (VLP) or viral replicon 
particle (VRP) might provide the best approach to creating an effective vaccine against N. 
gonorrhoeae (Zhu, Chen et al. 2011).   
Though vaccines for STIs remain controversial, the widespread use of the vaccine 
against human papilloma virus (HPV) might indicate a changing public opinion on the 
topic. Since being approved by the FDA in 2006, the two versions of the HPV vaccine 
have been given to approximately half of teenage girls (it was not initially approved for 
use in males). The topic of STI vaccines has already arisen with the development of this 
HPV vaccine. Thus when a vaccine for the prevention of gonorrhea is developed and 
approved, the public will hopefully be accepting and utilize it. 
 
1.11 Introduction to the dissertation 
Because of the important public health concerns associated with N. gonorrhoeae 
infections, it is important to further our understanding of the complex mechanism the 
pathogen uses to escape killing by antimicrobials. Emerging resistance to several 
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different classes of antibiotics portends a dismal future for the treatment of gonococcal 
infections. In order to design new therapeutics, we must first understand how resistance 
to current drugs developed. The goal of my work was to expand on our knowledge of the 
mechanisms of chromosomally mediated resistance, focusing primarily on β-­‐lactam	  resistance. 
 
1.11.1 Characterization of unique resistance determinants 
A study of clinical isolates of N. gonorrhoeae collected in New Caledonia, 
located in the Pacific Rim, revealed a group of strains with intermediate levels of 
resistance to penicillin. These strains, however, harbored unusual mutations in penB and 
mtrR and were missing the more common mutations. I examined the phenotypes of these 
strains and determined the contribution of these mutations to resistance. 
 
1.11.2 Characterization of genes found only in resistant strains of N. gonorrhoeae 
I performed comparative analyses on four different strains of N. gonorrhoeae: 2 
strains that are sensitive (FA19 and FA1090) and 2 that are resistant (FA6140 and 35/02) 
to penicillin. Interestingly, 55 unique genes/multi-gene clusters were present in both 
resistant strains but absent in the sensitive strains. I cloned each of these genes/multi-gene 
clusters into the gonococcal transfer/expression vector, pKH35, and transformed them 
into FA19 containing all of the known resistance determinants (FA19 penA mtrR penB 
ponA) and determined the penicillin MICs for each transformed strain. 
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1.11.3 Characterization of Factor X and high-level resistance 
Because we were unable to transform sensitive strains to high-levels of resistance, 
we concluded that Factor X was likely not a single gene event. I wanted to try to learn 
more about the mechanisms underlying this high-level penicillin resistance. I initiated a 
set of experiments in which I reverted each of the known resistance determinants in a 
resistant strain (FA6140) back to wild-type and examined the phenotypes of the resulting 
revertant strains. I also performed bacterial killing assays, did transformation 
experiments, and determined the MICs of a wide variety of antibiotics with various 
strains to determine if Factor X is specific for penicillin resistance or whether it 
contributes to resistance of other antibiotics as well.  
 
 
 
 
Chapter 2.  
Characterization of Novel Resistance Determinants in N. gonorrhoeae Isolates from 
New Caledonia 
 
2.1 Introduction 
Gonococcal infections are a widespread problem, with the World Health 
Organization estimating there to be > 60 million cases worldwide. The public health 
problem of N. gonorrhoeae is complicated by the documented ability of the organism to 
rapidly evolve to become resistant to antibiotics and to generate antigenic diversity 
among strains. As a naturally competent organism, N. gonorrhoeae can take up DNA 
from the environment and incorporate it into its genome through homologous 
recombination. Commensal bacteria in the natural mucosal flora and other Neisseria 
species within the human host provide DNA for the bacterium to use to create diversity 
within its genome, particularly among the components of the outer membrane in order to 
escape recognition and killing by the immune system (Hobbs, Seiler et al. 1994). The 
natural ability of the organism to modify its genome has been a major contributor to the 
development and spread of antibiotic resistance genes (Cannon and Sparling 1984). 
Penicillin was used to treat gonorrhea from the 1940’s until the early 1980’s. 
During this time, treatment with tetracycline was introduced because increased resistance 
to penicillin was routinely observed, but by the 1980s, widespread resistance to both 
antibiotics necessitated the move to other antibiotics. Since that time, the emergence of 
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resistance to nearly all major classes of antibiotics used to treat infections has followed, 
making N. gonorrhoeae an exeedingly difficult pathogen to treat. Penicillin resistance 
can arise via two different mechanisms: plasmid-mediated production of a beta-lactamase 
or chromosomally mediated transfer of resistance genes. Chromosomally mediated 
penicillin resistance, which is much more common than plasmid-mediated penicillin 
resistance, is also more complex and the mechanisms not fully elucidated. There are four 
known determinants (penA, mtrR, penB, ponA) and at least one unknown determinant that 
contribute to resistance. The four known determinants are transferred in a stepwise 
manner and individually increase resistance incrementally, but together cause a 
significant increase of ~400-fold. Both penA and ponA encode for altered forms of the 
two essential penicillin-binding proteins, causing a decrease in acylation and inhibition 
by β-lactam antibiotics (Dougherty, Koller et al. 1980; Ropp, Hu et al. 2002). Mutations 
in the regulatory region of the MtrC-MtrD-MtrE efflux pump (mtrR) result in 
overexpression of the pump, allowing the bacterium to more efficiently expel 
hydrophobic agents and antibiotics out of the cell (Pan and Spratt 1994). Finally, 
mutations in the major outer membrane porin, PorB1B, decrease permeation of the 
antibiotic across the outer membrane into the periplasm (Guymon, Walstad et al. 1978; 
Gill, Simjee et al. 1998). The unknown determinant cannot be transferred by homologous 
recombination, but it is required for high-level penicillin resistance found in clinical 
isolates. 
Similar to penicillin resistance, tetracycline resistance can be either plasmid-
mediated or chromosomally mediated. Plasmid-mediated resistance is due to the 
acquisition and expression of the tetM determinant from members of the genus 
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Streptococcus (Morse, Johnson et al. 1986). Chromosomally mediated tetracycline 
resistance involves several genes, but unlike penicillin resistance, the mechanisms of 
resistance are better understood. Both mtrR and penB are required for intermediate-level 
resistance (Maness and Sparling 1973; Sparling, Sarubbi et al. 1975). A third 
determinant, rpsJ1, encodes a point mutation in the ribosomal binding protein S10, and is 
responsible for high-level tetracycline resistance (Hu, Nandi et al. 2005). 
The major outer membrane porin of N. gonorrhoeae is either PorBIA or PorBIB, 
which are encoded by one of two alleles found at a single locus (porB1A and 
porB1B)(Knapp, Tam et al. 1984). Mutations in porB1B are important for resistance to both 
penicillin and tetracycline. Mutations in amino acids G120 and A121 of loop 3 of the 
protein are commonly observed and have been shown to reduce penicillin and 
tetracycline sensitivity (Olesky, Hobbs et al. 2002). Surprisingly, these penB mutations 
are phenotypically silent without a co-resident mtrR mutation (Olesky, Zhao et al. 2006; 
Shafer and Folster 2006). The MtrC-MtrD-MtrE efflux pump of N. gonorrhoeae is under 
transcriptional control of the MtrR repressor. The promoter for mtrR overlaps with the 
promoter for the mtrCDE operon (in the opposite direction). There is a 13-bp inverted 
repeat in the promoter region that serves as the binding site of the mtrR repressor (Lucas, 
Balthazar et al. 1997). While other mutations have been observed, by far the most 
common mutation in the mtr system is the deletion of a single nucleotide (-A) in the 13-
bp inverted repeat (Warner, Shafer et al. 2008). The deletion both increases mtrCDE 
transcription and ablates mtrR transcription (Veal, Nicholas et al. 2002). 
Public health officials in New Caledonia, located above Australia in the Pacific 
Rim, collected N. gonorrhoeae isolates over a three-year period to track the appearance 
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of known resistance alleles and monitor antibiotic resistance in the region. Historically, 
strains in this geographical area do not have the resistance alleles mentioned above and 
are still penicillin sensitive; thus penicillin G is still the most commonly used antibiotic 
for treatment of gonococcal infections. However, in this study, strains with intermediate 
level penicillin resistance were identified (MICpen = 0.133 mg/ml compared to MICpen = 
0.017 mg/ml for susceptible strains). When the known resistance alleles were examined, 
these strains lacked the common mutations in both mtrR and penB that are usually 
associated with chromosomally mediated resistance, but they did have a common penA 
determinant (Vernel-Pauillac, Nandi et al. 2008). Instead of the commonly observed -A 
deletion in the mtr promoter, these penicillin intermediate-level resistant New Caledonia 
strains had a single base pair insertion (+T) in that same region (Figure 2.1). Moreover, 
these strains had mutations in porB1B, but the common amino acid substitutions in loop 3 
of porB were not present in the New Caledonia penB, and different substitutions were 
present both in loop 3 and elsewhere (Figure 2.2). 
To determine the phenotypes of the novel mutations found in the mtrR and penB 
alleles isolated in New Caledonia, we compared strains with these mtrR and penB 
mutations to strains with the more common mutations in these genes. We show that the 
new mtrR mutation (+T in the inverted repeat of the promoter), in contrast to the –A 
mutation, does not contribute much to resistance to hydrophobic agents, and that the 
unusual penB allele found in the New Caledonia strains has a weaker phenotype than the 
more common penB alleles. Because New Caledonia is an isolated region, these new 
mutations appear to have arisen within the sexual network indigenous to this island 
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nation. As of present day, these mutations have not been found outside of the region and 
the more common mutations are not yet found in New Caledonia. 
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Figure 2.1 MtrR promoter sequences 
The sequences of the MtrR promoter for FA19 (penicillin sensitive), FA6140 (penicillin 
resistant), and 319 (New Caledonia) are shown. FA6140 harbors the –A deletion typical 
of pen-resistant strains while 319 contains the +T mutation. 
 
 
 
319  CATACACGATTGCACGGATAAAAAGTCTTTTTTTATAATCCGCCCTCGTCAAA!
     |||||||||||||||||||||||||||||||| ||||||||||||||||||||!
FA19 CATACACGATTGCACGGATAAAAAGTCTTTTT-TATAATCCGCCCTCGTCAAA!
 !
 !
FA19  CATACACGATTGCACGGATAAAAAGTCTTTTTTATAATCCGCCCTCGTCAAAC!
      ||||||||||||||||||| |||||||||||||||||||||||||||||||||!
FA6140CATACACGATTGCACGGAT-AAAAGTCTTTTTTATAATCCGCCCTCGTCAAAC!
!
!!!!!!!
!!!!!!!
mtrR%
mtrR%!35$ !10$
!A$
+T$
 Figure 2.2 penB sequences from New Caledonia strains 
Alignment of multiple penB alleles from New Caledonia and FA6140 and FA1090 (pen-sensitive). Red boxes highlight areas with 
significant sequence differences and * represents positions 120-121, where typical G120 and A121 penB mutations are found in 
penicillin-resistant strains. 
319       1 GASVAGTNSGWGNKQSFIGLKGGFGTIRAGSLNSPLKNTGSKVNAWESGKYTGELLEISK
361       1 GASVAGTNSGWGNKQSFIGLKGGFGTIRAGSLNSPLKNTGSKVNAWESGKYTGELLEISK
309       1 GASVAGTNSGWGNKQSFIGLKGGFGTIRAGSLNSPLKNTGSKVNAWESGKYTGELLEISK
307       1 GASVAGTNSGWGNKQSFIGLKGGFGTIRAGSLNSPLKNTGSKVNAWESGKYTGKLLEISK
FA1090    1 GASVAGTNTGWGNKQSFVGLKGGFGTIRAGSLNSPLKNTGANVNAWESGKFTGNVLEISG
FA6140    1 GASVAGTNTGWGNKQSFVGLKGGFGTIRAGSLNSPLKNTKDNVNAWESGKFTGNVLEISG
319      61 MAEREHRYLSARYDSPEFAGFSGSVQYAPKDNSGSNGESYHVGLNYRNNGFFAQYAGLFQ
361      61 MAEREHRYLSARYDSPEFAGFSGSVQYAPKDNSGSNGESYHVGLNYRNNGFFAQYAGLFQ
309      61 MAEREHRYLSARYDSPEFAGFSGSVQYAPKDNSGSNGESYHVGLNYRNNGFFAQYAGLFQ
307      61 MAEREHRYLSARYDSPEFAGFSGSVQYAPKDNSGSNGESYHVGLNYRNNGFFAQYAGLFQ
FA1090   61 MAQREHRYLSVRYDSPEFAGFSGSVQYAPKDNSGSNGESYHVGLNYQNSGFFAQYAGLFQ
FA6140   61 MAKREHRYLSVRYDSPEFAGFSGSVQYAPKDNSGSNGESYHVGLNYQNSGFFAQYAGLFQ
319     121 RYGEGTKKMEG--YSYNIPSLFVEKLQVHRLVGGYDNNALYASVAAQQQDAKLYQNQLVR
361     121 RYGEGTKKMEG--YSYNIPSLFVEKLQVHRLVGGYDNNALYASVAAQQQDAKLYQNQLVR
309     121 RYGEGTKKMEG--YLYNIPSLFVEKLQVHRLVGGYDNNALYASVAAQQQDAKLYQNQLVR
307     121 RYGEGTKKME---YLYNIPSLFVEKLQVHRLVGGYDNNALYASVAAQQQDAKLYQNQLVR
FA1090  121 RYGEGTKKIEYDGQTYSIPSLFVEKLQVHRLVGGYDNNALYVSVAAQQQDAKLYG--AMS
FA6140  121 RYGEGTKKIEYDGQAYSMPSLFVEKLQVHRLVGGYDNNALYVSVAAQQQDAKLYG--ATR
319     179 DNSHNSQTEVAATVAYRFGNVTPRVSYAHGFKGTVDSANH
361     179 DNSHNSQTEVAATVAYRFGNVTPRVSYAHGFKGTVDSANH
309     179 DNSHNSQTEVAATVAYRFGNVTPRVSYAHGFKGTVDSANH
307     178 DNSHNSQTEVAATVAYRFGNVTPRVSYAHGFKGTVDSANH
FA1090  179 GNSHNSQTEVAATAAYRFGNVTPRVSYAHGFKGTVDSANH
FA6140  179 VNSHNSQTEVAATAAYRFGNVTPRVSYAHGFKGTVDSANH
**"
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2.2 Materials and Methods 
2.2.1 Bacterial strains and DNA 
N. gonorrhoeae strains FA19 and FA1090 (penicillin-susceptible laboratory 
strains) and FA6140 (a clinical isolate with a MIC pen=4 µg/ml) have been described 
previously and were kindly provided by Dr. Fred Sparling, University of North Carolina 
at Chapel Hill (Maness and Sparling 1973; Danielsson, Faruki et al. 1986). FA19ΔmtrR 
was provided by Dr. William Shafer, Emory University. Genomic DNA from the New 
Caledonia strains was provided by Dr. Cyrille Goarant, Institut Pasteur de Nouvelle-
Calédonie. All strains used in this study are listed in Table 2.1.  
 
2.2.2 Bacterial media and growth conditions  
N. gonorrhoeae strains were grown on GC medium base (GCB) agar (Becton, 
Dickinson and Company; Sparks, MD) containing Kellogg’s supplements I and II at 37°C 
with 5% CO2 (Kellogg, Peacock et al. 1963). Liquid cultures of N. gonorrhoeae were 
grown in GC broth enriched with supplements I and II, supplement B, and 20 mM 
NaHCO3 in a shaking incubator at 37°C (Hafiz and McEntegart 1976). 
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Table 2.1 N. gonorrhoeae strains used in this study 
 
Strain Description 
FA1090 Pen and tet sensitive laboratory strain  
FA19 Pen and tet sensitive laboratory strain 
FA6140 CMRNG clinical isolate 
FA19 mtrR FA19 transformed with mtrR promoter mutation 
from FA6140 
FA19 mtrR(319) FA19 transformed with mtrR promoter mutation 
from 319 
FA19 ΔmtrR FA19 transformed with a plasmid containing a 
deletion in most of the coding region of mtrR. 
Described in Hagman 1995.  
FA19 penA mtrR FA19 transformed with penA and mtrR alleles from 
FA6140. 
FA19 penA mtrR porB1b FA19penAmtrR transformed with plasmid containing 
porB1b from FA1090 
FA19 penA mtrR porB6140 FA19penAmtrR transformed with porB1b from 
FA6140 (penB) 
FA19 penA mtrR porB319 #1 FA19penAmtrR transformed with porB1b from 319 
FA19 penA mtrR porB319 #2 same as above 
FA19 penA mtrR porB(A102S) FA19penAmtrR transformed with porB(A102S) mutant 
created by overlap PCR 
FA19 penA mtrR porB(N103K) FA19penAmtrR transformed with porB(N103K) mutant 
created by overlap PCR 
 
 
  
 70 
 
2.2.3 Preparation of DNA and PCR amplicands for genetic transformation 
Gonococcal strains were grown on GCB agar and chromosomal DNA was 
isolated using the Wizard™ Genomic Purification Kit (Promega Corporation; Madison, 
WI) according to manufacturer’s instruction.  
The promoter region of mtrR and the coding sequences of porBIB genes were 
amplified by PCR with specific oligonucleotide primers using Pfu polymerase. FA1090 
genomic DNA was used as a template in PCR reactions to create chimeras containing 
specific mutations. Chimeras containing the single porIB-A102S and porIB-N103K 
mutations and a construct containing both mutations together were constructed by 
overlap extension PCR (4-primer PCR, Figure 2.3). The porB1b allele from the New 
Caledonia strain 319 was amplified for transformation into FA19 penA mtrR and FA1090 
penA mtrR. Primers used for PCR are listed in Table 2.2. The products were analyzed by 
agarose gel electrophoresis and verified by sequencing. All PCR products were purified 
using the PureLink™ PCR Purification Kit (Invitrogen; Carlsbad, CA) according to 
manufacturer’s instructions. 
 
 
Table 2.2 Primers used for generation of mtr and porB mutants 
Primers used for PCR preparation of amplicands for genetic transformation of N. gonorrhoeae are listed. Primers were 
synthesized by Eurofins MWG Operon (Huntsville, Alabama). 
 
 
Primer Sequence (5’->3’ direction) 
5’PorB-A121S CCT GAA AAA CAC CGG CTC CAA CGT TAA CGC TTG GGA ATC CGG C 
3’PorB-A121S GCC GGA TTC CCA AGC GTT AAC GTT GGA GCC GGT GTT TTT CAG G 
G’PorB-N122K CCT GAA AAA CAC CGG CGC CAA AGT TAA CGC TTG GGA ATC CGG C 
3’PorB-N122K GCC GGA TTC CCA AGC GTT AAC TTT GGC GCC GGT GTT TTT CAG G 
5’PorB-AN>SK CCT GAA AAA CAC CGG CTC CAA AGT TAA CGC TTG GGA ATC CGG C 
3’PorB-AN>SK  GCC GGA TTC CCA AGC GTT AAC TTT GGA GCC GGT GTT TTT CAG G 
5’PorB-BsrGl/sil GGC TTC AGC GGC AGT GTA CAA TAC GCA CC  
3’ PorB-BsrGl/sil GGT GCG TAT TGT ACA CTG CCG CTG AAG CC 
PorB-Hind-Fwd GAG AAG CTT ACA AGA CTT CTC CAG CTT CC 
PorB-BamH-Rev AGA GGA TCC GGG TAA GTT TTA TCC ACG ACT 
mtr-up TTC AGA CGG CTG GAT GAT GCC GCC GAC TTG GC 
mtr-down GTC CAA GAA CCT CCT TCG GCA TCT 
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Figure 2.3 Overlap extension PCR to generate porB1b chimeras 
AB and CD fragments were generated in the first round of PCR using the A,B and C,D 
primer pairs, respectively. The two fragments were united in the second round of PCR 
using the outside primers, A and D. This method was used to generate the chimeric 
porB1bA102S, porB1bN103K, and porB1bAS>NK. 
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2.2.4 Genetic transformation 
To generate mtrR and porIB mutants in N. gonorrhoeae, genetic transformation of 
FA19 and FA19 penA mtrR was performed in GCB+ broth as described previously 
(Ropp, Hu et al. 2002). Briefly, cells from a -80°C frozen stock were streaked on GCB 
agar plates and incubated overnight at 37°C in 5% CO2. The next day, a single piliated 
colony was passaged onto a fresh GCB plate and allowed to grow for 12-18 hours. Cells 
were swabbed from the plate and gently resuspended in prewarmed GCB+ broth and 
diluted to a cell density of 1 x 108 colony forming units (cfu)/ml (OD560 nm of 0.18). 
Between 2.5-5 μg of donor DNA (either chromosomal or PCR product) was diluted to 
100 μl in 1X SSC and mixed with 900 μl of diluted cells in a round bottom polystyrene 
tube, with a loose lid to allow for aeration. Tubes were incubated for 5 h at 37°C in a 
humidified 5% CO2 atmosphere. Aliquots (300 μl) of the transformation mixture were 
then spread onto GCB agar plates containing various concentrations of penicillin and 
grown overnight at 37°C in 5% CO2. The next day, transformants were passaged onto 
fresh GCB plates. To verify positive transformants, individual colonies were resuspended 
in 30 μl of water, boiled for 5 minutes, and spun briefly to pellet the debris. Five 
microliters of the boilate supernatant was used as a PCR template and transformants 
showing correct recombination were confirmed by sequencing. 
 
2.2.5 MIC determinations 
Minimum inhibitory concentrations (MICs) of antibacterial agents were 
determined by the spot method on GCB agar containing antibiotics as previously 
described  (Ropp, Hu et al. 2002). Briefly, non-piliated (P-) colonies were passaged for 
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two days on GCB agar plates, then resuspended in GCB+ broth and diluted to 1 x 107 
cells/ml. Five microliters of diluted cells (50,000 cfu) were spotted onto GCB agar plates 
containing increasing concentrations of the appropriate antibiotic. The plates were 
incubated for 24 hours, and the MIC was defined as the minimal concentration of 
antibiotic at which no more than five colonies were observed following 24 hours of 
incubation. 
 
2.2.6 RNA extraction 
Gonococcal RNA was isolated and purified using a combined method of TRIzol 
(Invitrogen; Carlsbad, CA) and the RNeasy RNA extraction kit (Qiagen; Venlo, 
Netherlands). Liquid cultures of N. gonorrhoeae were grown in GCB broth as described 
above until they reached log phase (A560 = 0.4-0.5). Cells were harvested from 5 ml of log 
phase culture at 3000 x g for 5 min at 20oC and resuspended in 3ml RNA later (Ambion; 
Austin, TX). Following incubation at 4oC overnight, cells were pelleted and lysed with 
TRIzol (Invitrogen). Chloroform (1 ml) was added, and the phases were separated by 
centrifugation. The extracted RNA in the aqueous phase was further processed on the 
columns from the RNeasy Mini Kit according to manufacturer’s instructions. The RNase 
inhibitor RNasin Plus (Promega; Madison, WI) was used to preserve RNA integrity and 
the RQ1 DNase kit (Promega) was used to remove residual DNA contamination. The 
quantity and quality of the RNA were checked by A260 and the A260/ A280 ratio, as well as 
by visualization of the RNA on an agarose gel.  
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2.2.7 Real-time PCR 
cDNA samples for qRT-PCR were prepared from 1 mg of RNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Foster City, CA). 
Briefly, 10 μl of each RNA sample were mixed with random primers, dNTPs, RT buffer, 
and MultiScribe Reverse Transcriptase according to manufacturer’s instructions. The 
mixture was incubated at 25°C for 10 minutes, followed by 120 minutes at 37°, and 5 
seconds at 85°C. 
Real-time PCR was performed on an ABI Prism 7500 Fast Real Time sequence 
detection system (Applied Biosystems; Foster City, CA). The cDNA was diluted and 
100ng was combined with transcript specific primers and Absolute Blue™ QPCR Sybr 
green master mix (ABgene, Thermo Scientific; United Kingdom). Levels of the mtrC and 
mtrR transcripts were quantified using the comparitive CT method, with rnpB (which 
encodes for ribonuclease P) used as the endogenous control. Primers for real-time PCR 
are listed in Table 2.3. All transcripts were assayed in triplicate on independent biological 
replicates. 
Table 2.3 Primers used for real-time PCR 
Primers used for amplification of mtrC, mtrR, and rnpB are listed. Primers were synthesized by Eurofins MWG Operon 
(Hunstville, AL). 
 
Primer Sequence (5’->3’ direction) 
mtrC 565F GGC TTT ATC GGT CAG TCC AA 
mtrC 641R CGG ATG GTG GCT AAA ACA GT 
mtrR-forRT AAA ATT ACC GCC GTT TTG AC 
mtrR-revRT CCA ACG TCG ATT TGA TGA AG 
rnpB-F CGG GAC GGG CAG ACA GTC GC 
rnp-R GGA CAG GCG GTA AGC CGG GTT C 
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2.2.8 SDS Page and Western blotting 
N. gonorrhoeae cells were grown overnight on GCB plates. The following day the 
cells were scraped from the plates and resuspended in GCB+ broth, diluted to an OD560 of 
0.18, and 1 ml was removed and pelleted. The medium was removed, the pellet 
resuspended in 100 μl of SDS-PAGE loading buffer, and the samples were boiled for 5 
minutes to lyse the cells. Samples (10 μl) were loaded onto 10% SDS-polyacrylamide 
gels and separated by electrophoresis. Proteins were transferred from the gel onto a 
Hybond-Low Fluorescing PVDF membrane (GE Healthcare; Piscataway, NJ) in a semi-
dry transfer apparatus in 25 mM Tris, 102mM glycine, 10% methanol, 0.02% SDS. 
Following transfer, the membrane was blocked for 1h at 25°C in a phosphate-buffered 
saline with 0.1% Tween (PBS-T) and dry milk (5%). The membrane was then probed 
with a polyclonal MtrE-specific rabbit antibody (provided by Dr. Ann Jerse at Uniformed 
Services University of the Health Sciences) at 4°C overnight. PilW was used as a loading 
control. The blot was washed 3 times in PBS-T (PBS with 0.1% Triton X-100) and once 
in PBS, and the membrane was incubated for 2 h with an anti-rabbit Cy-3 labeled anti-
rabbit secondary antibody (GE Healthcare). The blot was imaged on the Typhoon 9400 
Imager (GE Healthcare) and ImageQuant software (GE Healthcare) was used for data 
analysis. 
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2.3 Results 
2.3.1 The –A mutation confers higher levels of resistance than the +T mutation 
N. gonorrhoeae strain FA19 was transformed with the PCR-amplified promoter 
region of mtr from the New Caledonia strain, 319, and levels of Triton X-100 just above 
the MIC (~250 µg/ml) were used for selection. Transformants were sequence-verified 
and their MICs were compared to MICs of FA19 containing the promoter from FA6140, 
a strain with the more common –A mutation. As shown in Figure 2.4, the +T insertion 
conferred high-level resistance to Triton X-100 (MIC > 16 mg/ml, the highest 
concentration that can be tested), but conferred only intermediate-level resistance to 
erythromycin (both Triton X-100 and erythromycin are subtrates of the MtrC-D-E efflux 
pump). In contrast, the –A deletion appears to have a stronger phenotype, conferring 
high-level resistance to both agents. 
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Figure 2.4 MICs of strains containing –A and +T mutations in the mtr promoter 
MICs of FA19 transformed with the mtr promoter regions of FA6140 (-A mutation) and a 
strain from New Caledonia, 319, (+T mutation) are shown. Both mutations give full 
resistance to Triton X-100 but the –A mutation confers higher resistance to erythromycin 
than the +T mutation does. 
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2.3.2 Effect of the +T mutation on transcription and translation of Mtr genes 
The +T mutation could have several distinct phenotypes: a) it could interfere with 
mtrR transcription, thus decreasing the amount of MtrR available for inhibition of 
mtrCDE transcription; b) it might block binding of MtrR to its operator, thus releasing its 
inhibitory block on mtrCDE transcription; or c) a combination of both. To investigate the 
effects of the +T mutation, we used quantitative real-time PCR to quantify RNA levels of 
the mtrR transcriptional repressor and of mtrC, the first gene of the mtrCDE efflux pump 
operon that is regulated by mtrR. We extracted RNA from four strains of N. gonorrhoeae 
with different mtr mutations for analysis. 
Both the –A and +T mutations significantly decreased transcript levels of mtrR, 
with the –A deletion resulting in the largest decrease. As expected, the strain containing 
an mtrR deletion showed no mtrR RNA levels. Moreover, these experiments showed that 
the –A deletion resulted in a 6-fold increase in transcription of mtrC over that in FA19, 
whereas the +T insertion resulted in only a 1.5-fold increase, similar to the increase seen 
in a ΔmtrR strain (Figure 2.5). 
We also used quantitative Western blotting to compare the effects of the +T and –
A mutations on protein expression of MtrE. Using whole cell lysates from the same four 
strains used in the RT-PCR studies, we probed blots with an antibody to MtrE. The levels 
of protein were consistent with our quantitative real-time rtPCR results: the -A deletion 
resulted in the largest increase in MtrE (12- fold over wild-type), while the +T insertion 
had a more modest effect, a 2-fold increase over wild-type, similar to the increase seen in 
the mtrR deletion strain (Figure 2.6).  
 
Figure 2.5 Transcription of mtrR and mtrC in strains with –A, +T, and Δmtr mutations. 
Results from quantitative real-time PCR are shown. Figure on left shows that mtrR transcription was absent in the mtrR deletion strain 
and decreased by about half in the strains with single amino acid deletions in the promoter. Transcription of mtrC was increased the 
most with a –A deletion. 
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Figure 2.6 Effect of +T mutation on expression of MtrC 
Quantitative Western blotting was performed to compare the effects of the -A and +T mutations on expression of the Mtr 
efflux pump. The -A increases expression more strongly than the +T does. 
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2.2.4 The effect of 319 penB on penicillin and tetracycline resistance 
Since unique mutations in porB1b have been identified in strains from New 
Caledonia, we explored the contributions of these mutations to resistance. We first 
transformed the porB1b  allele from strain 319 into FA19 penA mtrR. This recipient strain 
harbored the penA4 gene from the penicillin-resistant strain FA6140 along with the 
common –A deletion in the mtrR promoter region, because we have shown previously 
that the penB determinant requires the presence of the mtrR determinant to confer 
resistance. The MICs of penicillin and tetracycline were determined as shown in Figure 
2.7. The strain harboring the 319 porB1b allele exhibited intermediate resistance to 
penicillin but equivalent levels of resistance to tetracycline as the strain with the porB1b 
allele from FA6140. 
To determine which specific residues in the penB allele from the New Caledonia 
strain 319 are important for resistance, we first focused on the mutations found in loop 3 
of the New Caledonia porin. These mutations (A121S, N122K) were incorporated both 
individually and together into the wild-type porB1B allele from FA1090; the mutated 
porB1b alleles then transformed into FA19 penA mtrR. The MICs of penicillin and 
tetracycline were determined. As shown in Figure 2.8 the N122K mutation had no effect 
on resistance to penicillin or tetracycline, while the single A121S mutation conferred the 
same level of penicillin resistance as the penB allele from 319. In contrast, the A121S 
mutation  conferred only a portion of the full resistance to tetracycline, suggesting that 
resistance to tetracycline requires additional mutations. 
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Figure 2.7 MICs of FA6140 and 319 porB1b alleles to penicillin and tetracycline 
Transformation of porB1b alleles from FA6140 and 319 increased resistance to 
tetracycline equally. FA6140 penB increases resistance to penicillin more than 319 penB 
does. 
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Figure 2.8 Identification of mutations in penB important for resistance 
MICs of penicillin and tetracycline. Parental strain was FA19 penA mtrR. The A121S 
mutation is responsible for most of the resistance to penicillin, but additional mutations 
appear to be necessary for resistance to tetracycline. 
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2.2.6 The combined effects of the New Caledonia mutations 
We also created strains of FA19 penA containing the unique mtrR mutation (+T 
insertion) from strain 319 and the penB alleles from both FA6140 and 319. Surprisingly, 
there was no significant increase in resistance in any strain constructed with the +T 
insertion mutation, indicating that this allele is not capable of activating either porB allele 
(Figure 2.9). These data are consistent with the results above showing that the +T 
mutation only weakly increases mtrCDE transcription in comparison to the –A deletion. 
When we attempted to transform FA19 penA mtrR penB with genomic DNA from 
strain 319, no transformants were obtained. Since none of the known determinants from 
319 (penA, mtrR, penB) fully explained the increased resistance seen in this strain, 
another factor must play a role in penicillin resistance. We attempted to transform this 
unidentified determinant into FA19 but had no success, indicating that the cause of 
increased resistance is not transformable. This is consistent with our studies in other 
resistant strains, including FA6140 and 35/02. 
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Figure 2.9 Both the penB and the mtr mutations found in New Caledonia strains 
have weaker phenotypes than more common mutations 
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2.4 Discussion 
Because mutations in both mtr and porB1b are known to contribute to antibiotic 
resistance, these alleles are often sequenced among clinical isolates of N. gonorrhoeae. I 
characterized the unique mutations that had been found in the clinical isolates from New 
Caledonia with intermediate-levels of penicillin resistance. Our studies showed that the 
+T mutation in mtrR from strain 319 produces a much weaker phenotype than the more 
commonly found -A mutation does. We were able to show that this mutation increases 
resistance to erythromycin, penicillin, and tetracycline, but the increase is relatively 
small. Real-time quantitative PCR showed that the mtrR (+T) mutation increases 
transcription of mtrC by approximately 1.5 fold, while the -A mutation increases 
transcription by 6-fold. Quantitation of Western blot revealed a 2-fold increase in 
expression of MtrE with the +T mutation and a 12 fold increase with the -A mutation. 
The other resistance determinant from strain 319 with uncommon mutations, porB1B, 
increases resistance to penicillin but not to the levels seen with the porB1b allele from 
FA6140. The A121S mutation appears to be responsible for most of the resistance to 
penicillin but other porB mutations are likely required to achieve full resistance in 
tetracycline. The N122K mutation did not seem to play a role in resistance to either 
antibiotic. 
The New Caledonia strains examined here were a subset of large cohort of strains 
investigated for their resistance profiles and the sequence of their common resistance 
determinants. While none of the strains examined had high-level penicillin resistance, the 
subset of strains including strain #319 had much higher MICs of penicillin (0.136 µg/ml 
vs 0.017 µg/ml for the sensitive strains) than the others, and surprisingly they contained 
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unusual mutations in both their mtrR and penB determinants.  We set out to examine 
whether these unusual alleles were responsible for the higher than expected MICs, but in 
fact these determinants had much weaker phenotypes than the determinants from 
FA6140, a penicillin-resistant strain that we have characterized in much detail. When we 
transformed FA19 penA mtrR penB (irrespective of whether the determinants were from 
FA6140 or 319) with chromosomal DNA from 319 in anticipation that these strains 
contained an additional transformable determinant, no transformants with lower penicillin 
susceptibility could be selected even at the lowest selection concentration of penicillin. 
These data suggest that 319 and similar strains were likely clonal variants with higher 
intrinsic resistance to penicillin than “normal” wild-type gonococci. One intriguing 
possibility is that these strains contained the elusive Factor X, the non-transformable, 
potentially polygenetic determinant that is responsible for high-level resistance in 
FA6140. 
The importance of the mtr system to antibiotic resistance was first recognized in 
1974 (Maness and Sparling 1973). Proteins of the efflux pump were characterized over 
the next 20 years, but it was not until 1994 that the repressor MtrR was first described 
and the regulation of the mtr efflux pump by mtrR was implicated in antibiotic resistance 
(Pan and Spratt 1994). Several mutations in mtrR have been identified that increase 
resistance to various antibiotics. Other mutations in mtrR, including an insertion of a TT 
in the promoter or missense mutations in the coding region are associated with 
intermediate and low levels of antibiotic resistance, respectively (Hagman, Pan et al. 
1995; Hagman and Shafer 1995; Shafer, Balthazar et al. 1995; Warner, Shafer et al. 
2008). Before studies of these New Caledonia isolates performed by our lab and our 
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collaborators, the +T mutation was not linked to antibiotic resistance (Cousin, 
Whittington et al. 2003; Cousin, Roberts et al. 2004). However, our results clearly 
disagree with this conclusion and the +T mutation does increase resistance to antibiotics 
through modulation of the MtrC-D-E efflux pump expression. We have shown that the -A 
mutation has a stronger phenotype than +T mtrR promoter mutations found in the New 
Caledonia strains, contributing to higher levels of resistance to antimicrobials. 
It is interesting that even the weaker +T insertion in the promoter region of mtr, 
which increases MtrC-MtrD-MtrE expression by ~2-fold, gives full resistance to Triton 
X-100 without conferring full resistance to erythromycin or other antibiotics. While the 
implications of this result are unclear, apparently only a small change in mtrCDE 
transcription is capable of providing very high levels of resistance to detergents. Another 
possibility is that changes in mtrR transcription have effects on other proteins involved in 
Triton X-100 resistance. One such protein could be MtrF, which previously has been 
implicated in detergent resistance (Veal and Shafer 2003). 
Previous studies have shown that the porB1b allele is involved in antibiotic 
resistance. A mutation at position 120 (G→K) in FA6140 is critical for resistance; this 
mutation is not present in the New Caledonia strains (Olesky, Hobbs et al. 2002). In 
contrast, a new mutation in the New Caledonia strains not previously recognized as one 
involved in resistance, A121S, is responsible for reduced susceptibility to penicillin. 
Additional mutations, however, are required for resistance to tetracycline, but these 
mutations have not yet been characterized. 
One of the main differences between the -A and +T mutations in mtrR is the 
inability of the +T to activate mutations in porb1b. It has been clearly shown that penB 
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mutations do not increase resistance to penicillin or tetracycline in the absence of a co-
resident mtrR mutation (Olesky, Zhao et al. 2006). The mechanism of synergy between 
mtr and penB is unknown but presumably results in decreased influx of antibiotics. We 
were able to show that the -A mutation activated penB mutations in porB1b alleles from 
both FA6140 and strain 319, but conversely, the level of overexpression of the efflux 
pump provided by the +T mutation in strain 319 was not sufficient to activate the penB 
mutations. How strains in New Caledonia exhibit intermediate-levels of penicillin 
resistance without possessing an mtrR mutation capable of activating penB mutations is 
unclear. It is possible that they possess mutations in additional genes that are also capable 
of activating penB or that they utilize a completely different method of developing 
penicillin resistance.  
 
 
Chapter 3.  
Comparative overview of penicillin resistant and sensitive strains of Neisseria 
gonorrhoeae 
 
3.1 Introduction 
Though widespread penicillin resistance was first reported in Neisseria 
gonorrhoeae in 1987 and several groups (including ours) have studied the mechanisms of 
chromosomally-mediated β-lactam resistance, the mechanisms of high-level resistance 
are still not fully understood. The known resistance determinants (penA, mtrR, penB, and 
ponA) can be transferred from a resistant strain of N. gonorrhoeae (FA6140) to a 
sensitive strain (FA19) in the laboratory. Transformation with all of these determinants 
results in intermediate levels of resistance, but neither we nor others have been able to 
obtain transformants with donor-levels of resistance to penicillin. The inability to 
transform laboratory strains to donor levels of resistance has made elucidation of the 
mechanism of high-level resistance difficult. There are several possibilities to explain the 
inability to transform a recipient strain to the same level of resistance as the donor strain: 
1) two or more genes are required to increase resistance; 2) resistance is conferred by a 
gene that is absent in recipient strains and therefore not readily transformable; or 3) the 
flanking sequences surrounding a gene are different in the two strains, thus preventing 
efficient recombination. In this chapter, we tested the hypothesis that resistant strains 
contain a gene that confers resistance, and that this gene is absent in recipient strains. By 
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identifying, cloning and transferring these genes to a recipient strain containing the four 
known resistance determinants (penA, mtrR, penB, and ponA; MD4), we hoped to gain 
insight into the genes that might contribute to high levels of resistance. 
The recent advances in technology have made whole genome sequencing easier 
and more affordable, resulting in an increase in the availability of complete or partial 
genome sequences for many organisms. Neisseria species are capable of horizontal gene 
exchange and bioinformatics analyses have shown that commensal and pathogenic 
Neisseria share a large core genome (Marri, Paniscus et al. 2010). Beyond the core 
genome, many virulence genes are also shared between commensal and pathogenic 
species, though their roles in pathogenesis and virulence of the pathogens are not clear.  
In 2008-2009, the Broad Institute released drafts of the complete genome sequences of 
twelve strains of N. gonorrhoeae, allowing for more detailed studies and comparisons of 
different strains of the pathogens  (Broad Institute). Among these strains were several 
isolates that our lab studies, including two penicillin-resistant strains (FA6140 and 35/02) 
and two penicillin-susceptible strains (FA19 and FA1090) (Table 3.1). A comparison of 
the strains revealed a set of 67 genes, expressed in 55 operons, that are found in the 
resistant strains but absent in the sensitive strains (Figure 3.1). These genes/operons were 
cloned into FA19 containing the four known determinants (MD4; FA19 penA mtrR penB 
ponA) to determine if any of these unique genes increases resistance to penicillin. 
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Figure 3.1 Relationship between strains of N. gonorrhoeae 
The star indicates genes that are unique to resistant strains. 
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Table 3.1 Features of N. gonorrhoeae strains 
 
Genomic contents of four strains of N. gonorrhoeae are shown below. FA19 and FA1090 
are penicillin-susceptible strains while FA6140 and 35/02 are penicillin-resistant strains.  
 
Strain Size (nucleotides) Number of open reading frames 
FA19 2,099,891 2183 
FA1090 2,153,922 2002 
FA6140 2,033,960 2144 
35/02 2,043,737 2131 
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3.2 Materials and Methods 
3.2.1 Genome analysis 
A reciprocal protein Basic Local Alignment Search Tool (BLAST) (Altschul, 
Madden et al. 1997) analysis comparing the proteomes of FA19 and FA1090 with 
FA6140 and 35/02 was carried out with assistance from the UNC Bioinformatics Core. 
Follow-up analysis was done in our lab. We performed a reciprocal nucleotide BLAST 
analysis (Altschul, Gish et al. 1990) to narrow down the results from the protein BLAST 
as sequencing errors could introduce false positives into the protein BLAST results. 
Candidate genes were selected from the nucleotide search and were defined as genes 
found in both FA6140 and 35/02 but not found in either FA19 or FA1090. Candidate 
genes are listed in Table 3.3. All genome information was obtained from the Broad 
Institute or from The National Center for Biotechnology Information (NCBI). BLAST 
searches were performed through the NCBI Basic BLAST website (NCBI), using 
standalone coding, or using CLC Genomics Workbench 5.0 Software (CLC Bio; Aahrus, 
Denmark). 
 
3.2.2 Bacterial strains and plasmids 
FA19 and FA6140 were described in Chapter 2. Strain 35/02 is a penicillin-
resistant, cephalosporin intermediate-level resistant clinical isolate from Sweden, 
provided by Magnus Unemo of Örebro University Hospital, Örebro, Sweden. N. 
gonorrhoeae strain FA1090 is a well-characterized penicillin-sensitive clinical isolate 
used extensively in gonococcal studies (Nachamkin, Cannon et al. 1981; Hobbs, Sparling 
et al. 2011). 
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MD4 was created by transformation of FA19 with penA, mtrR, and penB PCR 
products using the transformation protocol described in Chapter 2. Penicillin was used for 
selection of penA, penB, and ponA* transformants. Triton X-100 was used to select for 
mtrR transformants. Transformants were verified by sequencing. To transform ponA* 
into MD3, a plasmid (pPR17) containing mutant ponA and an Ω cassette just downstream 
of the stop codon that confers resistance to spectinomycin and streptomycin was used. 
Positive transformants were selected for on GCB agar plates containing 100 μg/ml of 
spectinomycin. The Ω cassette was then removed by transforming again with PCR 
product of ponA* and screening colonies for loss of spectinomycin resistance. 
Transformants were verified by genomic DNA amplification and sequencing. 
Plasmid pKH35 was provided by Joseph Dillard from the University of 
Wisconsin at Madison. E. coli MC1061 cells were transformed with pKH35 containing 
each of the unique genes for transformation into MD4. 
 
3.2.3 Preparation of DNA and PCR amplicands for genetic transformation 
Primers were designed for each of the 55 operons listed in Table 3.3. Each 5’ 
primer included a PacI restriction site and approximately 10 bases of upstream sequence 
before the start codon, while each 3’ primer incorporated an XbaI restriction site 
following the stop codon to facilitate cloning into the pKH35 vector. Genomic DNA from 
FA6140 was extracted as described in Chapter 2. Genes were amplified from genomic 
FA6140 DNA using Pfu polymerase and the appropriate pairs primers. The PCR products 
were subcloned into the PacI and XbaI sites of the pKH35 vector and transformed into E. 
coli MC1061 cells. Because pKH35 contains a chloramphenicol resistance cassette, we 
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selected for positive transformants on LB agar plates containing 20 μg/mL 
chloramphenicol, and colonies appeared after incubation at 37 °C for 24-36 hours. 
3.2.3 Transformation of N. gonorrhoeae 
Despite repeated attempts, transformation of MD4 with pKH35 constructs was 
not possible, apparently due to MD4 having a lower transformation efficiency than FA19. 
As an alternative, we transformed each of the pKH35 constructs into FA19, following the 
same protocol described in Chapter 2. We selected for positive transformants on GCB 
agar plates with 0.2 μg/mL chloramphenicol, and these were verified by PCR 
amplification of boilates using pKH35 vector primers. Following verification of correct 
transformation, genomic DNA was prepared from each of the FA19-pKH35 strains and 
used to transform MD4. Chloramphenicol was again used for selection (0.6 μg/ml). 
 
3.2.4 MIC determinations 
The pKH35 vector puts genes under the control of an IPTG-inducible lac 
promoter. The plasmid recombines into the silent intergenic region between lctP and 
aspC (Stohl and Seifert 2001; Hamilton, Dominguez et al. 2005) (Figure 3.1). MICs were 
performed, following the same protocol described in Chapter 2. A second set of MICs 
were performed at the same time, with the addition of IPTG. Cells for the MICs with 
IPTG were grown the night before on GCB agar plates with 1mM IPTG. IPTG was also 
added to the antibiotic plates and added to the GCB+ broth used to dilute cells. 
Concentrations of penicillin between 0.125 and 1 .5 μg/mL were used to determine if the 
MIC of any of the new strains increased above that of MD4 (MIC = 0.7 μg/mL). MD4 
was included as a control in every MIC experiment. 
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Figure 3.2 Graphic map of pKH35  
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 Table 3.2 Genes found only in penicillin resistant strains of N. gonorrhoeae (not in sensitive strains) 
 
 
Gene number Gene name Size (nt) Best BLAST hit (if any) 
NGDG_0030 gene encoding conserved hypothetical 
protein 
237 Histone-like nucleoid-structuring protein 
(GC-NCCP11945) 
NGDG_0073 gene encoding predicted protein 201  
NGDG_0075 gene encoding predicted protein 165  
NGDG_0103 gene encoding predicted protein 174  
NGDG_0130 gene encoding predicted protein 186 gene encoding hypothetical protein (GC-
NCCP11945) 
NGDG_0164 gene encoding conserved hypothetical 
protein 
186 gene encoding hypothetical protein (GC-
NCCP11945) 
NGDG_0197 gene encoding conserved hypothetical 
protein 
186 gene encoding hypothetical protein (GC-
TCDC-NG08107) 
NGDG_0232 gene encoding predicted protein 165 gene encoding ferric enteric transporter 
binding protein (GC-NCCP11945) 
NGDG_0299 gene encoding predicted protein 228  
NGDG_0362 gene encoding predicted protein 195  
NGDG_0428 gene encoding conserved hypothetical 
protein 
420 N. meningiditis hypothetical protein 
NGDG_0547 gene encoding predicted protein 306 gene encoding hypothetical integral 
membrane protein (GC-TCDC-NG08107) 
NGDG_0676 gene encoding predicted protein 312 gene encoding putative phage associated 
protein (GC-TCDC-NG08107) 
NGDG_0677 gene encoding conserved hypothetical 
protein 
129 gene encoding hypothetical protein (GC-
NCCP11945) 
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NGDG_0678 gene encoding predicted protein 408 gene encoding putative phage associated 
protein (GC-NCCP11945) 
NGDG_0679 gene encoding conserved hypothetical 
protein 
1161 gene encoding hypothetical protein (GC-
NCCP11945, GC-TCDC-NG08107) 
NGDG_0688 gene encoding predicted protein 306  
NGDG_0704 gene encoding predicted protein 198  
NGDG_0721 gene encoding predicted protein 345 gene encoding mercury transport protein 
(GC-NCCP11945) 
NGDG_0739 gene encoding predicted protein 951  
NGDG_0762 gene encoding conserved hypothetical 
protein 
1436 gene encoding hypothetical protein (GC-
TCDC-NG08107) 
NGDG_0784 gene encoding alcohol dehydrogenase class-
III 
1132 gene encoding alcohol dehydrogenase 
class-III (GC-NCCP11945, GC-TCDC-
NG08107) 
NGDG_0813 gene encoding conserved hypothetical 
protein 
222 gene encoding HesB/YadR/YfhF family 
protein (GC-TCDC-NG0817) 
NGDG_0816 gene encoding conserved hypothetical 
protein 
495 gene encoding cell filamentation protein 
(GC-TCDC-NG0817) 
NGDG_0823 gene encoding twin-arginine leader-binding 
protein DmsD 
2219 gene encoding restriction modification 
protein Mod (GC-NCCP11945) 
NGDG_0873 gene encoding lysR family transcriptional 
regulator 
919  
NGDG_0874 gene encoding transposase 384  
NGDG_0876 gene encoding conserved hypothetical 
protein 
603 gene encoding hypothetical protein (GC-
TCDC-NG0817) 
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NGDG_0886 gene encoding hemagglutinin/hemolysin-
related protein 
5882  
NGDG_0887 gene encoding predicted protein 234 gene encoding hemagglutinin/hemolysin 
related protein 
NGDG_0888 gene encoding conserved hypothetical 
protein 
1851 gene encoding putative hemolysin 
activation protein HecB (GC-NCCP11945) 
NGDG_0891 gene encoding conserved hypothetical 
protein 
168  
NGDG_0904 gene encoding predicted protein 249 gene encoding putative phage associated 
protein (GC-TCDC-NG0817) 
NGDG_0905 gene encoding conserved hypothetical 
protein 
309  
NGDG_0906 gene encoding conserved hypothetical 
protein 
1997 gene encoding bacteriophage tail protein 
keratin 2a (GC-TCDC-NG0817) 
NGDG_0907 gene encoding predicted protein 228 gene encoding bacteriophage tail protein 
keratin 2a (GC-NCCP11945) 
NGDG_0908 gene encoding predicted protein 1248 gene encoding polyprotein (GC-TCDC-
NG0817) 
NGDG_0911 gene encoding predicted protein 645  
NGDG_0915 gene encoding predicted protein 1280  
NGDG_0917 gene encoding predicted protein 159 gene encoding putative oxidoreductase 
(GC-TCDC-NG0817) 
NGDG_1057 gene encoding predicted protein 162  
NGDG_1124 gene encoding conserved hypothetical 
protein 
345  
NGDG_1258 gene encoding conserved hypothetical 
protein 
135 gene encoding hypothetical protein (GC-
NCCP11945) 
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NGDG_1267 gene encoding predicted protein 246 gene encoding glutamate dehydrogenase 
(GC-TCDC-NG0817) 
NGDG_1296 gene encoding conserved hypothetical 
protein 
366 gene encoding hypothetical protein (GC-
TCDC-NG0817) 
NGDG_1297 gene encoding conserved hypothetical 
protein 
333 gene encoding hypothetical protein (GC-
TCDC-NG0817) 
NGDG_1298 gene encoding conserved hypothetical 
protein 
372 gene encoding hypothetical protein (GC-
TCDC-NG0817) 
NGDG_1364 gene encoding predicted protein 204 gene encoding hypothetical protein (GC-
NCCP11945) 
NGDG_1371 gene encoding predicted protein 150 gene encoding pyridine nucleotide 
transhydrogenase (GC-TCDC-NG0817) 
NGDG_1395 gene encoding transferrin-binding protein B 2097 partial tbpB gene for transferrin-binding 
protein B (GC strain 29528, GC-
NCCP11945) 
NGDG_1488 gene encoding conserved hypothetical 
protein 
180  
NGDG_1490 gene encoding predicted protein 495  
NGDG_1497 gene encoding predicted protein 243  
NGDG_1511 gene encoding predicted protein 183  
NGDG_1595 gene encoding predicted protein 285 gene encoding hypothetical protein SdaA 
(GC-NCCP11945) 
NGDG_1689 gene encoding outer membrane protein 708 gene encoding for N. gonorrhoeae outer 
membrane protein 
NGDG_1700 gene encoding conserved hypothetical 
protein 
117 gene encoding for hypothetical protein 
(GC-NCCP11945) 
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NGDG_1742 gene encoding conserved hypothetical 
protein 
1530  
NGDG_1746 gene encoding transposase 645 *Homo sapien DNA* 
NGDG_1756 gene encoding predicted protein 264 gene encoding hypothetical protein (GC-
NCCP11945) 
NGDG_1864 gene encoding predicted protein 462 gene encoding hypothetical protein (N. 
meningiditis H44/76) 
NGDG_1939 gene encoding predicted protein 153 gene encoding hypothetical protein (GC-
TCDC-NG08107) 
NGDG_1963 gene encoding conserved hypothetical 
protein 
879 gene encoding putative phage associated 
protein (GC-NCCP11945) 
NGDG_1978 gene encoding pilin 306 gene encoding pilS cassette (GC-
NCCP11945) 
NGDG_2013 gene encoding predicted protein 276  
NGDG_2014 gene encoding predicted protein 192  
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3.3 Results 
3.3.1 Results of BLAST searches 
Original results from the protein BLAST search returned 217 proteins found only 
in the resistant strains of N. gonorrhoeae. Because errors are less likely to influence 
nucleotide BLAST searches than protein BLAST searches, the four genomes were 
compared again at the nucleotide level. If a gene is the same in all four strains, the gene 
from Strain A must be a “top hit” in a BLAST search of Strains B, C, and D. Similarly, 
when the same gene from Strain B is used as the query, it must be a top hit when Strains 
A, C, and D are searched. This pattern of reciprocal BLAST searching yielded 67 genes 
(Table 3.2) that met the following criteria: 1) The gene was a top hit in a reciprocal 
nucleotide BLAST search between FA6140 and 35/02. 2) The gene did not appear in a 
nucleotide BLAST search against FA19 or FA1090.  
For subcloning into pKH35, I examined the locations of these genes in the 
FA6140 chromosome. Genes that were clustered together in what was likely the same 
regulon/operon were amplified as a unit, subcloned into pKH35, and transformed as one 
unit instead of as separate genes. This strategy was used because the genes would likely 
function as a unit, similar to the mtrCDE operon. The genes that were not part of an 
apparent operon were subcloned individually into pKH35 and transformed into MD4 as 
described in Materials and Methods. 
 
3.3.2 Effects of the 55 genes/multigene clusters on resistance 
Once all of the 55 genes/multigene clusters or operons were transformed into 
MD4, I performed MICs on all of the strains to determine any of these unique genes 
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contributed to resistance. Concentrations between 0.1 and 1.5 μg/mL were tested for each 
of the 55 transformants using a narrow dilution range (0.125, 0.25, 0.3, 0.4, 0.5, 0.6, 0.65, 
0.7, 0.75, 0.8, 0.85, 0.9, 1.0, 1.25, 1.5 μg/mL), particularly around the MIC of MD4. 
Unfortunately, none of these genes had an effect on resistance to penicillin. The MIC of 
penicillin for MD4 is 0.7 μg/mL, and none of the strains had MICs above 0.7 μg/mL. 
Because we used a narrow dilution range, it was unlikely that changes in the MIC were 
missed because of widely spaced penicillin concentrations. The MIC experiments were 
also performed with and without 1 mM IPTG to induce the expression of the cloned 
genes/gene clusters, since the pKH plasmid puts the inserted genes under control of the 
IPTG-inducible lac promoter. Once again, we observed no differences in the MIC values 
with or without IPTG. 
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3.4 Discussion 
Using a reciprocal BLAST search of the genome sequences from two penicillin-
susceptible strains (FA19 and FA1090) and two penicillin-resistant strains (FA6140 and 
35/02), we identified 67 unique genes shared by the two penicillin-resistant strains that 
were not in the genomes of the two penicillin-susceptible strains. These genes were 
cloned, transformed into a 4th level transformant (MD4), and their capacity to increase the 
MIC of penicillin up to the level of FA6140 or 35/02 was assessed. However, none of 
these genes or gen/clusters changed the MIC of penicillin in the transformants, indicating 
that none of these genes or clusters by themselves is involved in penicillin resistance. 
Although the 67 genes were unique to FA6140 or 35/02, it is not clear if these 
genes were still capable of transforming FA19 from genomic DNA. Since the hallmark of 
“Factor X” and high-level resistance is the inability to be transferred by transformation, 
one of the prerequisites is that the genes would not readily transfer between the two sets 
of strains. However, since many of the genes are small in size and should have had 
enough flanking DNA to undergo homologous recombination with FA19, these genes 
could potentially be transformed even though they did not exist in the recipient strain. 
This scenario is also consistent with our data showing that transfer of these genes into 
MD4 using the pKH35 plasmid had no effect on penicillin resistance.  
As shown in several studies, and discussed earlier in this dissertation, the penB 
mutation of porin is phenotypically silent without a co-resident mutation in mtrR. 
Similarly, the ponA* mutation identified by our laboratory is found in many resistant 
clinical isolates, but inserting it into a strain containing the other known resistance 
determinants (FA19 penA mtrR penB) does not increase resistance any further, indicating 
 108 
that expression of the ponA* phenotype is dependent on other, unidentified factors (Ropp, 
Hu et al. 2002). It is possible that the 67 genes identified in this study also depend on an 
additional gene or mutation to be present in order to express a phenotye. In this case, we 
would not see an increase in the MIC by adding each gene individually, but would have 
to test every possible combination of the 67 genes, or the 55 operons. Because of the low 
likelihood of this method producing significant results, and because of the extraordinary 
amount of effort and time this would take, we elected to not pursue this approach. 
There is still a possibility that might have seen a decrease in resistance in FA6140 
if we had inactivated the genes and examined the effects of the inactivation on resistance.  
However, due to the amount of time and effort to make strains with inactivated genes, we 
elected not to continue with this approach. Instead, as detailed in Chapter 4, we 
investigated high-level resistance from a different angle, and these experiments provided 
significant new insight into this phenomenon. 
The “Best BLAST Hit” of each of the 67 genes identified in the nucleotide 
BLAST is listed in Table 3.3; this table was updated at the time of writing this 
dissertation. Since the time when the original searches were performed, the two new N. 
gonorrhoeae genome sequences have been released with partial annotations: 
NCCP11945 and TCDC-NG08107 (Chung, Yoo et al. 2008; Chen, Hsia et al. 2011). At 
the time of our original bioinformatics studies, these sequences were not available and 
thus there were no matches to the genes in these strains. Interestingly, both of these 
strains are “multidrug resistant” strains of gonorrhea, though their MICs of penicillin 
have not been published. NCCP11945 was isolated in Korea while TCDC-NG08107 was 
isolated in Taiwan. If these strains exhibit high-levels of penicillin resistance, equivalent 
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or similar to those of FA6140 and 35/02, it would be interesting to include their genomic 
information in further studies.  
The gene NGDG_1746 from N. gonorrhoeae strain FA6140 actually aligned to 
human chromosomal DNA. This was discovered only recently because previous BLAST 
searches had been limited to microbial organisms. This same sequence has been 
identified in other N. gonorrhoeae by the Seifert group (Anderson and Seifert 2011). 
They identified this gene as having 90-100% identity to human retrotransposable element 
L1 (LINE-1). In their studies, they showed a relatively low penetrance of this gene in 
gonococcal isolates, explaining its absence from FA19 and FA1090 in our analyses. The 
effects, if any, of the insertion of this foreign DNA into the chromosome are not likely 
associated with antibiotic resistance. However, this is a good example of the far reaching 
ability of N. gonorrhoeae to use horizontal gene exchange to acquire new genetic 
information for various reasons. 
 
Chapter 4.  
Characterization of the mechanism of high-level penicillin resistance 
 4.1 Introduction 
Antibiotic resistance in the gonococci is a long-standing public health problem. 
As detailed in the introduction to this thesis, penicillin was really the first really effective 
antibiotic used to treat gonorrhea, and it remained so for 40 years. However, during that 
time, the MICs of penicillin for clinical isolates crept higher, until 1985, when an 
outbreak in the Durham bus station was found to be untreatable with penicillin (Faruki, 
Kohmescher et al. 1985). By 1987, penicillin had been removed as a treatment of choice 
by the Centers for Disease Control and Prevention. Other antibiotics, including 
tetracycline, azithromycin, and ciprofloxacin, also came and went on the approved 
treatment list, such that by 2007, only one class of antibiotics, the expanded-spectrum 
cephalosporins (in particular, ceftriaxone and cefixime) were the only antibiotics left on 
the recommended list. The appearance of strains with very high MICs for ceftriaxone 
does not bode well for future treatment of gonorrhea (Ohnishi, Golparian et al. 2011; 
Unemo, Golparian et al. 2012). 
The mechanism of resistance to penicillin in the gonococci is complex and multi-
faceted. Resistance can be transferred in a step-wise manner from a resistant donor strain 
to a susceptible recipient strain by DNA uptake and homologous recombination. These 
types of studies have identified four genes involved in penicillin resistance: penA 
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(mutations in PBP 2), mtrR (promoter mutation that increases expression of the MtrC-
MtrD-MtrE efflux pump), penB (mutations in the porB1B allele that decrease antibiotic 
permeation into the periplasm, and ponA (mutation in PBP 1). Even when these four 
genes are transferred, the MIC of penicillin increases to 0.75 µg/ml, well below the donor 
level of resistance (MIC = 4 µg/ml). However, as detailed in this dissertation, 
transformation to higher levels of resistance has not been achieved, and this inability to 
identify the genetic mechanism of high-level resistance has markedly hindered our ability 
to understand the cellular mechanisms at play. 
We have referred to the gene(s) involved in this last step of high-level resistance 
as “Factor X”. As detailed in Chapter 3, there are several possibilities that explain the 
inability to transfer high-level resistance to susceptible strains by transformation: 1) two 
or more genes are required to increase resistance; 2) resistance is conferred by a gene that 
is absent in recipient strains and therefore not readily transformable; or 3) the flanking 
sequences surrounding a gene are different in the two strains, thus preventing efficient 
recombination. Studies in Chapter 3 investigated the possibility that resistance was due to 
a gene absent in the recipient strain, but the results from those studies indicated that such 
genes by themselves were not responsible for resistance.  
Since transformation of Factor X is not possible, in this Chapter I initiated studies 
to learn more about the cellular mechanism of Factor X. Specifically, we asked 1) 
whether resistance mediated by Factor X was dependent on the known resistance 
determinants, and 2) whether Factor X resistance was specific for penicillin or other β-
lactam antibiotics, or if it conferred resistance to other antibiotics as well. To address the 
first question, we created a series of step-wise revertants of FA6140 in which each of the 
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four known resistance determinants was reverted back to wild-type in a stepwise manner. 
This allowed for the comparison of known resistance determinants with and without the 
effect of Factor X at each level (Figure 4.1). To address the second question, we 
examined the MICs of a wide range of antibiotics, both bacteriostatic and bactericidal, for 
FA6140 and the highest level transformant of MD4 for each particular antibiotic. These 
studies revealed new insight into how Factor X increases resistance.  
 
  4.2 Materials and Methods 
4.2.1 Bacterial strains and plasmids 
Strains FA19 and FA6140 have been described earlier in this dissertation. Strains 
MD1, MD2, MD3, and Strain MD4 were constructed by step-wise transformation of 
FA19 with PCR products of each of the four known resistance determinants amplified 
from FA6140, as described in Chapter 3. In all cases, correct transformation was verified 
by PCR amplification of genomic DNA and sequencing. 
Revertant strains of FA6140 were created by replacing each of the four known 
resistance determinants in a step-wise manner with its corresponding wild-type allele. To 
replace ponA* with the wild-type ponA gene, a plasmid (pPR16WT; Figure 4.1) containing 
wild-type ponA and an Ω cassette just downstream of the stop codon that confers 
resistance to spectinomycin and streptomycin was used to transform FA6140. Positive 
transformants (referred to hereafter as MDrev3) were selected on GCB agar plates 
containing 100 μg/mL spectinomycin (Ropp, Hu et al. 2002). The next determinant, 
penB, was reverted to wild-type PorB1B by transforming MDrev1 with pBScat-1090PIB, 
which contains the porB1b gene from FA1090, a kanamycin resistance cassette just past 
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the stop codon, and ~500 bp of flanking sequence on both ends of the gene (Figure 4.1) 
(Olesky, Hobbs et al. 2002). Transformants (referred to as MDrev2) were selected on 
GCB agar plates with 40 μg/mL kanamycin. 
Reverting the last two determinants, mtrR and penA, back to wild-type was not as 
straight-forward as there was no selection marker for transformants. To revert mtrR back 
to wild-type, FA19 genomic DNA was amplified with primers flanking the mtr promoter 
region, and transformation was performed according to our standard laboratory protocol 
as described earlier. Because of the lack of selection available, a reverse selection method 
was used to identify correct transformants. The transformation mixture was diluted and 
plated on plain GCB agar plates to obtain individual colonies. The following day, 
approximately 250 colonies were streaked onto GCB plates with or without 8 μg/mL 
Triton X-100. Colonies that grew on Triton X-100 plates after 24 hours were considered 
to be negative (i.e. they still harbored the mtrR mutation from FA6140). Colonies that did 
not grow on Triton X-100 plates but did grow on plain GCB plates contained the wild-
type mtrR promoter sequence. 
A plasmid, puc18us-penA (courtesy of Joshua Tomberg) was used to in the final 
step in the reversion of FA6140. This plasmid contains the wild-type penA gene from 
FA19 and the N. gonorrhoeae uptake sequence to facilitate transformation and 
homologous recombination. The QuikChange Method (Stratagene; Carlsbad, CA) was 
used to incorporate silent restriction sites into the penA gene (Tomberg, Unemo et al. 
2010), which were utilized to screen for correct transformants (Figure 4.1). MDrev3 
(FA6140 with wt ponA, penB, mtr) was transformed with puc18us-penA and plated on 
plain GCB plates. The next day, approximately 300 colonies were passaged onto GCB 
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agar plates containing 0.25 μg/mL penicillin and onto plain GCB agar plates. Colonies 
that did not grow on the penicillin plates but did grow on the plain plates were considered 
positive for the wild-type penA gene. Boilates were prepared from positive transformants 
and the penA gene was amplified by PCR. To verify that the wild-type penA gene had 
recombined into the genome, the PCR products were digested with BamHI and XhoI 
(New England Biolabs; Ipswich, MA), which are two of silent restriction sites in the 
penA clone. Clones that appeared positive by digest were verified by sequencing. 
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Figure 4.1 Plasmids used to generate FA6140 reversion strains 
pPR16 was used to transform wt-ponA into FA6140. pBScat-1090PIB was used to 
transform wt-porB into MDrev1 (FA6140-wtponA). FA19 penA with silent restriction 
sites is shown in the third panel. 
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Table 4.1 Strains and plasmids used in this study 
Strain Description 
FA19 Pen and tet sensitive laboratory strain 
FA6140 CMRNG clinical isolate 
FA19-pIB  FA19 transformed with pBScat-1090PIB+3’kan 
MD1-pIB FA19pIB transformed with FA6140 penA PCR product 
MD2-pIB MD1-pIB transformed with FA6140 mtrR PCR product 
MD1 FA19 transformed with FA6140 penA PCR product 
MD2 FA19 transformed with FA6140 penA PCR product 
MD3 FA19 transformed with FA6140 penA, mtrR, penB PCR 
products 
MD4 MD3 transformed with FA6140 ponA* PCR product 
MDrev3 FA6140 transformed with pPR16 (wt-ponA) 
MDrev2 MDrev1 transformed with pBScat-1090PIB+3’kan 
MDrev1 MDrev2 transformed with FA19 mtrR PCR product 
MDrev0 MDrev3 transformed with puc18us-FA19penA 
pPR16 plasmid containing wild-type FA19 ponA and Ω fragment 
for streptomycin/spectinomycin resistance 
pBScat-1090PIB+3’kan plasmid containing FA1090 porB1b allele and kanamycin 
resistance cassette 
puc18us-penAwt plasmid containing GC uptake sequence and FA19penA 
with silent restriction sites throughout penA coding 
sequence 
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4.2.2 MIC determinations 
The MICs of a range of antibiotics for the two series of strains in FA19 (MD1-
MD4) or FA6140 (MDrev1-MDrev4) containing each of the different resistance 
determinants were determined as described in Chapter 2. 
 
4.2.3 Transformation of MD4 
When examining resistance to different antibiotics, it was necessary to transform 
MD4 with FA6140 DNA to be sure that there were no additional resistance determinants 
(other than penA, mtrR, penB, and ponA) in FA6140 that provided increased resistance to 
the antibiotic. We followed the genomic transformation protocol described in Chapter 2 
to transform MD4 to the highest levels of resistance for each antibiotic tested in these 
studies. Briefly, piliated MD4 cells were incubated with genomic DNA extracted from 
FA6140. After five hours, the transformation mixture was plated on a concentration of 
the appropriate antibiotic slightly higher than the MIC (determined previously). Plates 
were checked after 24 and 48 hours for the presence of colonies. 
 
4.2.4 Bactericidal killing curves 
Gonococcal cells were grown in liquid medium and time-kill measurements after 
the addition of various antibiotics were performed as previously described (Crenn, 
Meyran et al. 1994).  Briefly, GCB broth was inoculated with N. gonorrhoeae cells at a 
density of 108 CFU/mL. Cultures were incubated in a shaking incubator at 37 °C for 
approximately one hour, or until OD560 = 0.25-0.3. At this point, cultures were re-diluted 
to 108 CFU/mL and allowed to grow for two hours. After two hours, a 1mL aliquot was 
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removed and diluted to OD560 = 0.18. Aliquots were plated on GCB agar plates and 
incubated at 37 °C. Antibiotics at concentrations twice the MICs were added to flasks 
containing aliquots of the original liquid culture. One flask without antibiotic was used as 
a control. Flasks were kept in the shaking incubator and samples were removed and 
plated on GCB agar at 1, 2, and 4 h. Colonies were counted after 24 hours and the cfu/mL 
were calculated. 
Experiments involving thiourea and 2,2’-dipyridyl (Sigma-Aldrich; St. Louis, 
MO) were identical to the antibiotic killing curves. Either thiourea or 2,2’-dipyridyl were 
added to flasks with the antibiotics at the same time. N. gonorrhoeae was grown with 
thiourea and with 2,2’-dipyridyl to ensure that the compounds did not negatively affect 
bacterial growth at the concentrations used.  
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4.3 Results 
4.3.1 The phenotype of Factor X is expressed independently of other resistance 
determinants 
 
To determine whether the phenotype of Factor X was dependent on any of the 
known resistance determinants, each of the known determinants in FA6140 was reverted 
back to wild-type in a step-wise manner and the MICs of the revertant strains were 
compared to strains of FA19 containing the same known resistance determinants (Figure 
4.2). Thus, the only difference in resistance determinants between the strains being 
compared (e.g. MD3 vs MDrev3 or MD2 vs MDrev2) is Factor X. 
As shown in Figure 4.3, the MIC of penicillin was 2-4 fold higher in each of the 
FA6140 revertant strains compared to the corresponding FA19 strains, indicating that the 
phenotype of Factor X for conferring penicillin resistance is expressed independently of 
the other determinants. Likewise, the MICs of chloramphenicol, ciprofloxacin, 
tetracycline and rifampin for the revertant strains were also consistently 2- to 4-fold 
higher than the corresponding FA19 strains containing the same known determinants. In 
contrast, the MIC of erythromycin was equivalent for the FA19 and FA6140 strains 
lacking mtrR mutations (Figure 4.3). 
 
 Figure 4.2 Stepwise transfer and reversion of chromosomally mediated resistance genes 
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The left side of this figure shows the FA19 series of strains that have an increasing number of resistance determinants. MD1 
has only the first determinant, penA. MD2 has the first two determinants, penA and mtr. MD3 and MD4 have penB and 
ponA added, respectively. The right side of the figure depicts a series of strains in which each of the known determinants in 
FA6140 was reverted back to wild-type in a step-wise manner. The nomenclature is the same as for the FA19 series: The 
number in the strain name indicates how many known resistance determinants are present. For example, MDrev3 is the 
FA6140 parental strain with the ponA-wild-type allele, the three remaining determinants (penA, mtr, and penB) are still 
present.  
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Figure 4.3 MICs of paired FA19 transformants and FA6140 revertants 
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4.3.2 Factor X influences the MICs of some, but not all, antibiotics 
 
To ensure that differences were not due to any other transformable mutations, 
MD4 was transformed with genomic DNA from FA6140 and transformants were selected 
on concentrations of the antibiotic just above the MIC for MD4. For example, we have 
shown that there is an additional resistance determinant for tetracycline, rpsJ1, which 
encodes an altered S10 ribosomal protein (Hu, Nandi et al. 2005). As shown in Figure 
4.3, when the rpsJ1 allele from FA6140 was introduced into MD4, the MIC of 
tetracycline was equivalent to the donor strain, FA6140. In contrast to tetracycline, we 
were unable to obtain transformants for the antibiotics chloramphenicol, ciprofloxacin, 
penicillin, or rifampin. Thus, as shown in Figure 4.4, donor levels of resistance were 
obtained with the highest transformant of MD4 (MD4 x FA6140 gDNA) for 
erythromycin and tetracycline, but not with chloramphenicol, penicillin, ciprofloxacin, 
and rifampin. 
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Figure 4.4 MICs of transformants of MD4 with FA6140 DNA 
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4.3.3 Effects of various antibiotics on the growth of N. gonorrhoeae in liquid culture 
The results from Figure 4.4 indicate that two antibiotics, erythromycin and 
tetracycline, have the same MIC for both FA6140 and the highest transformant of MD4. 
These two antibiotics are usually bacteriostatic, whereas most of the antibiotics that do 
not have the same MICs for the two strains are generally considered to be bactericidal. To 
determine their mode of action in N. gonorrhoeae, we diluted log-phase liquid cultures of 
FA6140 to OD560 = 0.1, added the different antibiotics at twice their MIC, and determined 
the cfu/mL for the cultures every hour for 4 hours. As shown in Figure 4.5, cells with no 
antibiotic continued to grow, as expected. Cultures treated with erythromycin or 
tetracycline were arrested in growth but did not decrease the cfu/mL, indicating that these 
drugs are bacteriostatic for N. gonorrhoeae. In contrast, chloramphenicol, ciprofloxacin, 
penicillin, and rifampicin all killed the cells as shown by the decrease in cfu/mL of the 
treated cultures, demonstrating that they are bactericidal for N. gonorrhoeae.  
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Figure 4.5 Time-kill curves of N. gonorrhoeae treated with various antibiotics 
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4.3.4 Effects of iron chelators and hydroxyl radical quenchers on survival of N. 
gonorrhoeae treated with antibiotics in liquid culture 
 
The data from the MIC, transformation, and kill-curve experiments indicate that 
Factor X confers non-specific resistance to bactericidal antibiotics but has no effect on 
bacteriostatic drugs. These data are highly reminiscent of recent studies in E. coli 
showing that bactericidal (but not bacteriostatic) antibiotics kill by a common mechanism 
of action involving the production of hydroxyl radicals (OH) and metabolic stress 
(Kohanski, DePristo et al. 2010). Thus, no matter the pathway bactericidal antibiotics 
inhibit, they all kill the bacteria at concentrations near their MIC by a common metabolic 
stress mechanism.  
To investigate whether the formation of OH was involved in bactericidal 
antibiotic killing of N. gonorrhoeae, we performed kill-curve assays in the presence 
thiourea, a selective OH scavenger (Repine, Fox et al. 1981; Novogrodsky, Ravid et al. 
1982; Wasil, Halliwell et al. 1987). As shown in Figure 4.6, the addition of thiourea 
prevented the killing of FA6140 by two bactericidal antibiotics with different 
mechanisms of action, penicillin and ciprofloxacin, whereas thiourea had no effect on the 
bacteria treated with the bacteriostatic antibiotic, tetracycline. 
Hydroxyl radicals are formed when an electron is transferred from ferrous iron 
(Fe2+) to hydrogen peroxide through the Fenton reaction (Imlay 2003). To demonstrate 
that the production of OH upon the addition of bactericidal antibiotics was a result of the 
Fenton reaction, we performed kill curve experiments with the same antibiotics as above 
in the presence of the iron chelator, 2,2’-dipyridyl, which inhibits the Fenton reaction by 
chelating free iron within the cell (Imlay, Chin et al. 1988). Similar to our results with 
thiourea, 2,2’-dipyridyl protected N. gonorrhoeae from killing by the bactericidal 
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antibiotics, penicillin and ciprofloxacin, but had no significant effect on the bacteria 
treated with the bacteriostatic antibiotic, tetracycline (Figure 4.6). 
 
 
 Figure 4.6 Effects of thiourea and 2,2’-dipyridyl on growth of N. gonorrhoeae treated with antibiotics 
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4.4 Discussion 
When we started the experiments outlined in this chapter, we knew very little 
about the characteristics of Factor X, outside of the fact that high-level resistance to 
penicillin was not transferrable by homologous recombination. We asked whether Factor 
X required any of the other known determinants to exert its resistance phenotype, and 
whether it was specific for β-lactam antibiotics or also mediated resistance to other 
antibiotics. The surprising results indicated that Factor X provides higher resistance to all 
bactericidal antibiotics and does not depend on other resistance determinants. Finally, we 
showed that N. gonorrhoeae is killed by bactericidal antibiotics by initiation of an 
oxidative stress mechanism that involves released Fe2+ and formation of hydroxyl 
radicals. 
To provide corroborating evidence that bactericidal antibiotics kill N. 
gonorrhoeae by release of Fe2+ and formation of hydroxyl radicals, we treated liquid 
cultures of N. gonorrhoeae with either thiourea (a selective hydroxyl radical scavenger) 
or 2,2’-dipyridyl (an iron scavenger), and both of these compounds protected gonococci 
from killing by bactericidal antibiotics. These data are similar to results reported by 
Kohanski, et al., who showed that bactericidal antibiotics induce cell death of E. coli 
through the production of hydroxyl radicals (OH). Hydroxyl radicals are deadly to 
bacterial cells, causing damage mainly to DNA, but also to membranes, proteins, and 
lipids (Imlay 2003). 
Many groups have studied the oxidative stress defense mechanisms of N. 
gonorrhoeae, but the mechanisms are quite different from those of E. coli, which are 
much better understood. N. gonorrhoeae is exposed to reactive oxygen species (ROS) 
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produced by commensal bacteria in its host environment, ROS from human immune 
system defenses, and ROS and reactive nitrogen species (RNS) as byproducts of its own 
metabolic processes. Many genes have been identified as important either for protection 
from or in response to oxidative damage. For example, catalase and peroxidase are 
important for detoxifying H2O2 and Mn2+ quenches O2− (Seib, Wu et al. 2006). However, 
bacteria do not have a defined mechanism for destroying OH (Dwyer, Kohanski et al. 
2009). Studies in E. coli showed that treatment with fluoroquinolones resulted in up-
regulation of genes involved in O2− stress, iron-sulfur cluster synthesis, and iron uptake. 
O2− levels in the cell are increased by increased metabolic activity, such that the normal 
cellular defenses against O2− damage are overwhelmed. Ferric iron (Fe3+) is reduced to 
ferrous iron (Fe2)+ in the Haber-Weiss reaction, and Fe2+ is then free to oxidize H2O2 
through the Fenton reaction to form OH, which kills the bacterial cells (Dwyer, 
Kohanski et al. 2007; Dwyer, Kohanski et al. 2009) (Figure 4.7).  
Superoxide and hydroxyl radicals were first implicated in cellular death caused by 
fluoroquinolones. Further studies showed that all bactericidal antibiotics, regardless of 
their target, also caused death through generation of damaging hydroxyl radicals. This 
common mechanism of cell death has been reported in E. coli and also in Staphylococcus 
aureus (Kohanski, Dwyer et al. 2007). Although further studies are needed, we can 
tentatively add N. gonorrhoeae to the list of bacteria in which bactericidal antibioitcs 
cause death through hydroxyl radical formation. 
Though the studies described here do not directly demonstrate an antibiotic-
dependent increase in OH formation in N. gonorrhoeae, our results do show a direct 
decrease in bactericidal antibiotic killing when cultures were protected from toxic effects 
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of OH. We also showed that the bacterium responds to the two different classes of 
antibiotics differently, and that Factor X increases resistance non-specifically to 
bactericidal antibiotics but does not have an effect on bacteriostatic antibiotics. We were 
unable to transform to high levels of resistance for all bactericidal antibiotics tested, and 
the resistant strain with all resistance determinants reverted to wild-type had a 2- to 4-fold 
higher MIC than the sensitive strain for all bactericidal drugs. 
Based on these observations, we propose a mechanism for Factor X related to 
oxidative stress defenses in the pathogen: Resistant strains, such as FA6140, have 
developed mechanisms of protecting against oxidative stress more efficiently than 
sensitive strains, such as FA19. Since all bactericidal agents, independent of the target, 
kill by producing ROS and thus damaging DNA, proteins, and membranes, resistant 
strains of N. gonorrhoeae likely change the regulation of some set of genes involved in 
DNA repair, cell wall synthesis, or iron regulation and a higher concentration of 
antibiotic is necessary for killing. Because this is not a single, or even double, gene event, 
it has been impossible to transform to levels of high resistance in the laboratory. Studies 
to identify which genes are regulated in response to bactericidal antibiotics in N. 
gonorrhoeae will be introduced Chapter 5. 
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Figure 4.7 Proposed model of oxidative stress response in N. gonorrhoeae 
 
Under normal conditions (top panel) O2− is produced during respiration and in response 
to the environment. Defenses include superoxide dismutase (SOD) and (Mn), which in 
turn produce H2O2. Catalases (kat) and peroxidases (Prx) detoxify peroxide. When treated 
by bactericidal antibiotics (bottom panel), increased metabolism and respiration and 
cellular responses result in an increase in O2−, overwhelming the oxidative stress 
defenses. Ferrous iron is released and reacts with H2O2 to produce OH. Figure adapted 
from (Seib, Wu et al. 2006; Dwyer, Kohanski et al. 2009) 
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Chapter 5.  
Conclusions and future directions 
5.1 Transcriptome sequencing of N. gonorrhoeae 
5.1.1 Introduction 
The data I have presented in this thesis has centered on understanding the genetic, 
biochemical, and mechanistic aspects of high-level penicillin resistance in the pathogenic 
organism, N. gonorrhoeae. We established that the bacterium responds differently to 
bactericidal and bacteriostatic antibiotics and that Factor X is involved only in resistance 
to bactericidal drugs. We were able to transform a sensitive strain to levels of donor 
resistance for bacteriostatic drugs, but could not reach the same levels of resistance of 
bactericidal drugs. Furthermore, we reverted each of the known resistance determinants 
in a resistant strain (FA6140) back to wild type and observed that the phenotype of Factor 
X was independent of any known determinants.  
Multiple studies have shown that all bactericidal drugs kill E. coli through the production 
of hydroxyl radicals. When normal cellular defense mechanisms are overwhelmed, 
excess oxidants build up within the bacterial cell. Hydroxyl radicals are formed through 
the interaction of excess hydrogen peroxide and reduced iron in the Fenton reaction. We 
have also shown that in N. gonorrhoeae, all bactericidal drugs also kill by producing 
hydroxyl radicals and that the effects of these drugs can be blocked by the addition of 
substances that inhibit the Fenton reaction (thiourea or 2,2’-bipyridyl).  
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These results led us to examine the role of oxidative and metabolic stress pathways in the 
-cidal action of the antibiotics, and our data support a role of hydroxyl radical formation 
in this process. Based on our results, we hypothesize that FA6140 does not initiate the 
metabolic stress response until higher levels of antibiotic are present compared to FA19 
and FA1090, and that this difference is due to up-regulation or higher expression of 
important proteins that help delay the metabolic stress response. To better understand the 
gonococcal response to antibiotic treatment, we sequenced the transcriptomes of FA6140 
and MD4 (FA19 penA mtrR penB ponA*) under normal and penicillin-stressed 
conditions, allowing us to compare the transcriptomes of a penicillin-resistant and a 
penicillin-sensitive strain under normal and penicillin-stressed conditions. The 
experiments and data described here represent our first attempts to understand the 
transcriptome of FA6140 compared to MD4 and to glean from these data potential 
mechanisms that underlie the resistance phenotype of FA6140. 
 
5.1.2 Materials and Methods 
Liquid cultures of N. gonorrhoeae were grown as described above. Upon reaching 
log phase, MD4 and FA6140 cultures were each divided into two 250 mL baffled flasks. 
One flask of each strain was treated with penicillin. MD4 was treated with 0.175 μg/mL 
and FA6140 was treated with 1 μg/mL of penicillin for 1 hr; these concentrations were 
selected from earlier trials because they inhibited the growth of cells, indicating that they 
were placing stress on the cells without killing them. Cells were harvested from 5 ml of 
culture at 3000 x g for 5 min at 20oC and resuspended in 3ml RNA later (Ambion; 
Austin, TX). Following incubation at 4oC overnight, cells were treated with 10 mM Tris-
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HCl, 1 mM EDTA (TE buffer) plus 0.2 mg/mL lysozyme. The SpinSmart RNA 
Purification kit (Denville Scientific; Metuchen, NJ) was used to extract RNA according 
to manufacturer instructions.  After purification, the RNase inhibitor RNasin Plus 
(Promega; Madison, WI) was used to preserve RNA integrity and the RQ1 DNase kit 
(Promega) was used to remove residual DNA contamination. Both the quality and 
quantity of RNA were determined by A260 and A260.280 ratio respectively. The 
MicrobExpress bacterial mRNA enrichment kit (Ambion) was used to remove 16S and 
23S rRNA by following the manufacturer’s protocol. The UNC High Throughput 
Sequencing Facility performed two rounds of transcriptome sequencing using the 
Illumina HiSeq 2000 and the Illumina Genome Analyzer II (Illumina; San Diego, CA). 
 
5.1.3 RNA-seq results 
We used two alignment methods to map reads from the sequencing data to the N. 
gonorrhoeae genome sequence. Because FA1090 is well annotated in NCBI, it was 
chosen as the primary reference genome for aligning sequencing reads. Galaxy is a public 
server that allows users with minimal programming experience to run computational 
analyses on large datasets (Giardine, Riemer et al. 2005; Blankenberg, Von Kuster et al. 
2010; Goecks, Nekrutenko et al. 2010). CLC Genomics Workbench 5.0 software was 
used for additional analysis (CLC Bio; Aahrus, Denmark). Once reads were aligned to 
FA1090, comparisons were made between penicillin-treated and -untreated samples of 
MD4 and FA6140 to determine changes in gene expression caused by antibiotic 
treatment. We were most interested in genes with a 2-fold or greater change in 
expression, by reads per kilobase of transcript per million-mapped-reads (RPKM).  
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Interestingly, more genes had increased expression in MD4 than FA6140 when 
treated with penicillin (36 vs. 15) (Table 5.1). These results led to the hypothesis that 
FA6140 might express higher levels of oxidative stress response genes under normal 
conditions than MD4 does. If this were the case, there might not be a difference in gene 
expression upon addition of penicillin or other bactericidal antibiotics, because the 
bacterium is already primed and ready for attack by the antibiotic. To test this, we 
compared the transcriptomes of MD4 and FA6140. This comparison showed 274 genes 
that have higher basal levels of expression in FA6140 while only 56 are expressed at 
higher levels in MD4 (Table 5.2).  
Many of the genes expressed at higher levels in FA6140 encode for proteins that 
might help to protect the cell from oxidative stress and antibiotic attack. For example, 
several proteins are involved in DNA repair mechanisms or cell wall/membrane 
biogenesis. Hydroxyl radicals induce death by damaging DNA, membranes, and proteins. 
With the upregulation of genes involved in repairing and regenerating these essential 
cellular components, FA6140 might be more capable of protecting itself from hydroxyl 
radical mediated damage than is MD4. 
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Table 5.1 Genes with increased expression in FA6140 in response to penicillin 
treatment 
 
 
NGO0228 Hypothetical protein other/unknown 
NGO0492 phage associated protein other/unknown 
NGO0797 transcriptional regulator transcription 
NGO1095 phage associated protein other/unknown 
NGO1115 phage associated protein other/unknown 
NGO1136 hypothetical protein cell wall/membrane biogenesis 
NGO1208 NgoMIIIM restriction endonuclease 
NGO1209 DNA-cytosine methyltransferase replication, recombination, repair 
NGO1313 hypothetical protein other/unknown 
NGO1623 phage associated protein other/unknown 
NGO1633 phage associated protein other/unknown 
NGO1634 phage associated protein other/unknown 
NGO1635 phage associated protein other/unknown 
NGO1636 phage associated protein replication, recombination, repair 
NGO1739 hypothetical protein replication, recombination, repair 
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Table 5.2 Genes with increased expression in MD4 in response to penicillin 
treatment 
 
 
fxsA phage T7 exclusion suppressor other/unknown 
hslO Hsp33-like chaperonin posttranslational modification 
NGO0228 hypothetical protein other/unknown 
NGO0375 phosphoglucomutase carbohydrate transport/metabolism 
NGO0376 peptidyl-prolyl cis-trans isomerase B posttranslational modification 
NGO0457 hypothetical protein other/unknown 
NGO0475 phage associated protein other/unknown 
NGO0476 phage associated protein other/unknown 
NGO0477 phage associated protein transcription  
NGO0478 phage associated protein other/unknown 
NGO0479 lambda repressor protein transcription  
NGO0487 phage associated protein other/unknown 
NGO0488 phage associated protein other/unknown 
NGO0554 hypothetical protein other/unknown 
NGO0854 hypothetical protein other/unknown 
NGO0879 hypothetical protein other/unknown 
NGO1014 phage associated protein Transcription 
NGO1015 phage associated protein transcription 
NGO1046 ClpB protein posttranslational modification 
NGO1095 phage associated protein other/unknown 
NGO1096 phage associated protein other/unknown 
NGO1105 phage associated protein other/unknown 
NGO1115 phage associated protein other/unknown 
NGO1208 NgoMIIIM restriction endonuclease 
NGO1209 DNA-cytosine methyltransferase replication, recombination, repair 
NGO1244 MarR family transcriptional regulator transcription 
NGO1422 heat shock protein posttranslational modification 
NGO1496 transferrin-binding protein B other/unknown 
NGO1564 hypothetical protein other/unknown 
NGO1633 phage associated protein other/unknown 
NGO1634 phage associated protein other/unknown 
NGO1770 oligopeptidase A other/unknown 
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Table 5.3 Genes with increased basal levels of expression in FA6140 compared to 
MD4 
Genes are classified according to predicted function by COG (Clusters of Orthologous 
Groups) analysis (Natale, Galperin et al. 2000; Tatusov, Galperin et al. 2000). 
 
 
Replication, recombination, and repair  
NGO0007 putative type II restriction endonuclease 
NGO0300 putative very-short-patch-repair endonuclease  
NGO0485 putative replicative DNA helicase, putative 
phage associated protein  
NGO0545 putative type III restriction-modification system 
methyltransferase  
NGO0738 putative DNA-damage-inducibile protein  
NGO0771 putative exodeoxyribonuclease V alpha subunit  
NGO0973 putative DNA polymerase III, epsilon chain  
NGO1074 MafI protein 2  
NGO1146 putative phage associated protein  
NGO1157 IS1016 transposase  
NGO1256 IS1016 transposase  
NGO1259 DNA topoisomerase IV subunit A  
NGO1412 IS1016 transposase  
NGO1437 primosome assembly protein PriA  
NGO1648 Irg7  
NGO1795 DcmB  
NGO1907 hypothetical protein 
NGO1987 hypothetical protein 
radC  
rdgC  
recX  
 
 
Amino acid transport and metabolism 
avtA valine-pyruvate transamidase 
NGO0444 threonine dehydratase  
NGO0532 hypothetical protein 
NGO0835 GNA1162   
NGO1182 putative nitrogen regulatory protein P-II  
NGO1241 histidinol-phosphate aminotransferase  
NGO1329 aromatic amino acid aminotransferase  
NGO1600 glutamine synthetase 
NGO1773 hypothetical protein  
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NGO1808 D-amino acid dehydrogenase small subunit  
NGO2013 putative ABC transporter, ATP-binding 
protein 
 
Posttranslational modification and protein turnover 
anmK anhydro-N-acetylmuramic acid kinase 
NGO0132 NrdG protein 
NGO1372 cb-type cytochrome c oxidase subunit IV 
NGO1656 hypothetical protein NGO1656  
 smpB SsrA-binding protein 
 
 
Coenzyme transport and metabolism 
bioD dithiobiotin synthetase 
hemC porphobilinogen deaminase 
NGO0360 hypothetical protein 
NGO0857 putative dihydroneopterin aldolase  
 NGO1307 DNA/pantothenate metabolism flavoprotein 
NGO1483 8-amino-7-oxononanoate synthase  
NGO1508 pyridoxal phosphate biosynthetic protein 
 
 
Translation 
def peptide deformylase 
NGO0208 hypothetical protein  
NGO0549 hypothetical protein  
NGO1330 tRNA (uracil-5-)-methyltransferase  
NGO1783 RluC  
NGO1831 50S ribosomal protein L29  
NGO1842 elongation factor Tu  
NGO1870 methionyl-tRNA formyltransferase 
rplA 50S ribosomal protein L1 
rplL 50S ribosomal protein L7/L12 
rpsB 30S ribosomal protein S2 
rpsL 30S ribosomal protein S12 
truB tRNA pseudouridine synthase B 
Carbohydrate transport and metabolism 
eno phosphopyruvate hydratase 
gmhA phosphoheptose isomerase 
NGO0142 putative sugar transporter  
NGO1911 hypothetical protein  
NGO2076 putative glucokinase  
pgi  glucose-6-phosphate isomerase 
 143 
pgk phosphoglycerate kinase 
ppnK inorganic polyphosphate/ATP-NAD kinase 
Energy production and conversion 
gltA type II citrate synthase 
NGO0143 hypothetical protein  
NGO0651 hypothetical oxidoreductase 
NGO0734 putative oxidoreductase  
NGO0890 D-lactate dehydrogenase  
NGO0893 putative oxidoreductase  
NGO0923 
putative succinate dehydrogenase flavoprotein 
subunit  
NGO0984 hypothetical protein  
NGO1024 hypothetical protein  
NGO1026 putative ferredoxin  
NGO1279 nitroreductase 
NGO1413 
Na(+)-translocating NADH-quinone reductase 
subunit A  
NGO1414 
Na(+)-translocating NADH-quinone reductase 
subunit B  
NGO1417 
Na(+)-translocating NADH-quinone reductase 
subunit E  
NGO1442 
ethanol-active dehydrogenase/acetaldehyde-
active reductase 
NGO1521 putative acetate kinase  
NGO1525 methylcitrate synthase  
NGO1741 NADH:ubiquinone oxidoreductase subunit K 
NGO1743 NADH dehydrogenase subunit I  
NGO1751 NADH:ubiquinone oxidoreductase subunit A 
NGO1775 putative ferredoxin 
NGO2031 PetC 
 
 
Nucleotide transport and metabolism 
hemH 
phosphoribosylaminoimidazole-
succinocarboxamide synthase 
NGO0589 putative ABC transporter, permease protein  
NGO0748 
putative phosphoribosylaminoimidazole 
carboxylase catalytic subunit  
NGO1183 phosphoribosylformylglycinamidine synthase  
NGO1876 aspartate carbamoyltransferase regulatory subunit  
NGO2009 putative permease protein  
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nrdB ribonucleotide-diphosphate reductase subunit beta 
 
Cell wall/membrane biogenesis 
lnt apolipoprotein N-acyltransferase 
lolB outer membrane lipoprotein LolB 
mraY 
phospho-N-acetylmuramoyl-pentapeptide-
transferase 
NGO0205 LolA  
NGO0344 GTP-binding protein LepA  
NGO0418 putative glycosyl transferase  
NGO0534 alginate O-acetylation - like protein 
NGO0626 putative murein hydrolase  
NGO0815 
putative UDP-N-acetylmuramate: L-alanyl-
gamma-D-glutamyl-meso-diaminopimelate 
ligase  
NGO0834 hypothetical protein NGO0834  
NGO0987 ADP-heptose--LPS heptosyltransferase II  
NGO1216 diacylglycerol kinase  
NGO1801 hypothetical protein   
 
 
Cell cycle control and mitosis 
maf Maf-like protein 
NGO0653 hypothetical protein  
NGO1659 hypothetical protein  
 
 
Transcription 
NGO0007 putative type II restriction endonuclease  
NGO0288 RNA polymerase factor sigma-32  
NGO0801 putative ribonuclease  
NGO1407 AsnC family transcriptional regulator  
NGO1850 DNA-directed RNA polymerase subunit beta'  
 
 
Inorganic ion transport and metabolism 
NGO0363 putative stress-sensitive restriction system protein  
NGO0542 hypothetical protein  
NGO1195 EriC protein 
NGO1433 putative ABC transporter, permease protein  
NGO1581 putative transport protein  
NGO1769 CcpR  
NGO2088 
putative ABC transporter, ATP-binding protein, 
enterobactin  
NGO2090 putative ABC transporter, permease protein 
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trkA 
potassium transporter peripheral membrane 
component 
 
Signal transduction mechanisms 
NGO0176 putative two-component system sensor kinase  
NGO0541 putative phage associated protein  
NGO1064 hypothetical protein   
NGO1298 hypothetical protein  
NGO1382 putative GTP pyrophosphokinase  
NGO1866 nitrogen assimilation regulatory protein NtrX 
NGO0181 
putative sec-independent protein translocase 
component  
NGO0184 HitA 
NGO1156 hypothetical protein  
 
 
Defense mechanisms 
NGO0237 N-acetyl-anhydromuranmyl-L-alanine amidase  
NGO0395 multidrug efflux protein  
NGO0407 putative type I site-specific deoxyribonuclease  
NGO0546 
putative type III restriction-modification system 
endonuclease protein  
NGO0186 putative zinc-binding alcohol dehydrogenase 
NGO1249 alkylhydroperoxidase 
NGO1879 putative bacteroicin resistance protein 
 
 
Other/undefined 
NGO0033 hypothetical lipoprotein 
NGO0039 hypothetical protein  
NGO0046 hypothetical protein  
NGO0049 hypothetical protein  
NGO0054 hypothetical protein  
NGO0055 pilus-associated protein  
NGO0121 hypothetical protein  
NGO0130 hypothetical protein  
NGO0163 hypothetical protein  
NGO0232 hypothetical protein  
NGO0252 hypothetical lipoprotein 
NGO0302 hypothetical protein  
NGO0315 hypothetical protein  
NGO0342 hypothetical protein  
NGO0357 hypothetical protein  
NGO0377 putative transport protein  
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NGO0391 hypothetical protein  
NGO0422 hypothetical protein  
NGO0454 hypothetical protein  
NGO0455 hypothetical protein  
NGO0461 hypothetical protein  
NGO0465 putative phage associated protein  
NGO0472 putative phage associated protein 
NGO0474 putative phage associated protein 
NGO0482 putative phage associated protein 
NGO0484 putative phage associated protein 
NGO0510 putative phage associated protein 
NGO0511 hypothetical protein 
NGO0527 hypothetical protein 
NGO0613 hypothetical protein 
NGO0640 RmsR 
NGO0666 hypothetical protein 
NGO0678 hypothetical lipoprotein 
NGO0709 hypothetical protein 
NGO0729 putative phage associated protein 
NGO0746 putative O-methyltransferase 
NGO0780 hypothetical protein 
NGO0791 hypothetical protein 
NGO0811 hypothetical protein 
NGO0842 hypothetical protein 
NGO0843 hypothetical protein 
NGO0919 hypothetical protein 
NGO0927 hypothetical protein 
NGO0937 hypothetical protein 
NGO1005 putative phage associated protein 
NGO1010 putative phage associated protein 
NGO1011 putative phage associated protein 
NGO1025 hypothetical protein 
NGO1037 hypothetical protein 
NGO1062 hypothetical protein 
NGO1107 putative phage associated protein 
NGO1121 putative phage associated protein 
NGO1130 putative phage associated protein 
NGO1139 putative phage associated protein 
NGO1150 hypothetical protein 
NGO1166 putative phage associated protein 
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NGO1215 hypothetical protein 
NGO1257 hypothetical protein 
NGO1293 hypothetical protein 
NGO1306 hypothetical protein 
NGO1346 hypothetical protein 
NGO1348 hypothetical protein 
NGO1352 3-oxoacyl (acyl-carrier protein) synthase 
NGO1370 integral membrane protein 
NGO1385 hypothetical protein 
NGO1386 hypothetical protein 
NGO1388 hypothetical protein 
NGO1449 LctP 
NGO1459 hypothetical protein 
NGO1463 hypothetical protein 
NGO1491 integral membrane protein 
NGO1503 hypothetical protein 
NGO1584 MafB3 
NGO1585 MafB4 
NGO1586 hypothetical protein 
NGO1591 hypothetical protein 
NGO1593 hypothetical protein  
NGO1595 hypothetical protein 
NGO1597 hypothetical protein 
NGO1620 putative phage associated protein 
NGO1629 putative phage associated protein 
NGO1630 putative phage repressor protein 
NGO1642 putative phage associated protein 
NGO1643 putative phage associated protein 
NGO1645 putative phage associated protein 
NGO1647 putative phage associated protein 
NGO1681 hypothetical protein 
NGO1692 hypothetical protein 
NGO1719 hypothetical protein 
NGO1726 hypothetical protein 
NGO1753 hypothetical protein 
NGO1760 hypothetical protein 
NGO1847 hypothetical protein 
NGO1849 hypothetical protein 
NGO1861 hypothetical protein 
NGO1865 DNA processing protein 
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NGO1872 hypothetical protein 
NGO1874 hypothetical protein 
NGO1880 hypothetical protein 
NGO1931 GapC 
NGO1938 hypothetical protein 
NGO1955 hypothetical protein 
NGO2004 hypothetical protein 
NGO2010 hypothetical protein 
NGO2016 hypothetical protein 
NGO2017 hypothetical protein 
NGO2047 hypothetical lipoprotein 
NGO2075 homoserine kinase 
NGO2086 hypothetical protein 
NGO2113 hypothetical protein 
NGO2118 outer membrane transport protein 
NGO2120 NTP binding protein 
NGO2123 hypothetical protein 
NGO2125 putative acyltransferase 
NGO2135 putative transglycosylase 
NGO2137 putative ABC transporter 
NGO2168 3-oxoacyl-(acyl carrier protein) synthase III 
NGO2170 hypothetical protein 
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5.1.4 Discussion and future directions 
We are currently testing the hypothesis that penicillin-resistant strains of N. 
gonorrhoeae, such as FA6140, are able to more efficiently handle damage caused by 
oxidative stress than penicillin-sensitive strains, such as MD4 and FA19. The results of 
the transcriptome analysis indicated that FA6140 expresses many genes involved in 
protection from oxidative stress as well as genes that might assist the bacterium with 
repairing damage caused by oxidative stress. To determine if the increased expression of 
these genes is responsible for the increased resilience of FA6140 to antibiotic killing, we 
plan on cloning these genes into a gonococcal expression and targeting vector to 
overexpress them in MD4. If they do indeed induce a protective effect, the MIC of 
penicillin will increase when these genes are expressed at higher levels in MD4. 
Our studies have demonstrated a clear role for hydroxyl radical-mediated killing 
of N. gonorrhoeae by bactericidal antibiotics. We have shown that different strains, such 
as FA6140 and MD4, have very different responses to the same antibiotics. To further 
understand these differences, we have obtained plasmids from Dr. Ann Jerse at 
Uniformed Services University of the Health Sciences to knock-out several oxidative 
stress response genes. We will utilize these plasmids to knock-out catalase (kat), 
cytochrome C peroxidase (ccp), the manganese transporter (mntC), and methionine 
sulfoxide reductase (msrA) in both FA6140 and MD4. These genes are known be 
important for detoxifying oxidants that cause damage to N. gonorrhoeae cells, but their 
roles in protection against attack by antibiotics, if any, have not yet been tested. We 
hypothesize that since bactericidal antibiotics kill N. gonorrhoeae through oxidative 
stress mechanisms and the production of hydroxyl radicals, these genes will confer 
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protection against bactericidal antibiotics and conversely, when these genes are absent, 
the MICs of these antibiotics will drop. Because FA6140 might have higher expression 
levels of other genes that protect against oxidative stress, the MICs of bactericidal 
antibiotics might not decrease for this strain upon the knock-out of kat, sodB, or gor.  
 
5.2 General discussion and conclusions 
N. gonorrhoeae has evolved with man and been an important pathogen for 
thousands of years. The bacterium has developed mechanisms to evade the human 
immune system, allowing it to successfully avoid killing and establish infections that can 
cause serious complications for the host. Gonorrhea infections are most often localized to 
the genital tract, but if left untreated, can lead to pelvic inflammatory disease, ectopic 
pregnancy, and infertility in women, as well as disseminated gonococcal infections in 
both sexes. The ability of N. gonorrhoeae to develop antibiotic resistance to antibiotics 
makes treating gonococcal infections difficult. 
Two mechanisms of antibiotic resistance have been identified in the gonococcus. 
Plasmid-mediated resistance involves the acquisition of a plasmid harboring a gene that 
inactivates the antibiotic. This mechanism of resistance has been identified for both 
penicillin and tetracycline. Chromosomally mediated resistance, which is more common 
and more complicated, involves the step-wise acquisition of several resistance 
determinants. Chromosomally mediated resistance to penicillin has been studied 
extensively but is still not fully understood. Four determinants that contribute to 
intermediate levels of resistance have been identified. 1) penA, which encodes for an 
altered form of penicillin-binding protein 2 (PBP 2), the primary target of penicillin; 2) 
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mtrR, which is most often a mutation in the promoter of the MtrC-MtrD-MtrE efflux 
pump, resulting in its overexpression; 3) penB, which encodes for mutations in the major 
outer membrane porin that decrease influx of antibiotics into the periplasm; and 4) ponA, 
which encodes a mutated form of PBP 1, the other essential PBP in N. gonorrhoeae. 
Transfer of these four determinants from a resistant strain to a susceptible strain in the 
laboratory is possible and results in intermediate levels of resistance. However, despite 
multiple attempts by several labs, including ours, transformation to levels of resistance 
equivalent to the donor strain has not been possible. The goals of my studies were to 
develop a deeper understanding of the known determinants mtrR and penB and also to 
characterize high-level penicillin resistance. 
I characterized unique mtrR and penB mutations identified in a group of N. 
gonorrhoeae strains isolated in New Caledonia with intermediate levels of penicillin 
resistance. In studies described in Chapter 2, I showed that the New Caledonia mtrR and 
penB determinants had much weaker phenotypes than the determinants from FA6140, a 
well characterized penicillin-resistant strain. penB mutations are dependent on a co-
resident mtrR mutation (Olesky, Zhao et al. 2006), but the unique mutation in the New 
Caledonia mtrR determinant was unable to activate penB mutations, indicating that 
another mechanism is involved in resistance in these strains.  
In chapter 3, I used bioinformatics tools to analyze and compare the genome 
sequences of resistant and sensitive strains of N. gonorrhoeae. Reciprocal protein and 
nucleotide BLAST analyses demonstrated that there were 67 genes, found in 55 
transcriptional units, found exclusively in penicillin-resistant strains of the bacterium. To 
determine if these genes contributed to resistance, I transformed each of them into MD4, 
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a penicillin-sensitive strain containing the four known resistant determinants. I performed 
MIC experiments on each of the transformed strains, but results showed that none of 
these genes increased resistance to penicillin. 
Studies in Chapter 4 were designed to further characterize the cellular 
mechanisms behind high-level penicillin resistance. Because of the inability to transform 
to donor levels of penicillin resistance in the lab, identification of “Factor X”, or the 
gene(s) causing high levels of resistance has not been possible. Experiments to learn 
more about how Factor X mediates high-level resistance were designed and carried out. 
A series of step-wise revertants of FA6140 was created, in which each of the four known 
resistance determinants was reverted back to wild type in a step-wise manner. By 
comparing these strains with a series of strains containing the same resistance 
determinants transformed into a sensitive strain, I was able to demonstrate that the 
phenotype of Factor X is independent of any of the four known resistance determinants. I 
next determined the MICs of FA6140 and the highest-level transformant possible for 
several antibiotics. The results showed that MD4 could be transformed to the levels of 
resistance for FA6140 for all of the bacteriostatic antibiotics tested, but I was unable to 
reach full donor levels of resistance for any of the bactericidal antibiotics. Finally, I 
showed that N. gonorrhoeae is killed by bactericidal antibiotics through an oxidative 
stress mechanism that involves damage to the cell by the formation of hydroxyl radicals. 
To better understand why FA6140 is able to better fight off attack by bactericidal 
antibiotics, I have initiated ongoing studies in our lab that are based on results of 
transcriptome analysis of FA6140 and MD4, both with and without penicillin stress.  
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My original search to define “Factor X” as a single gene that contributes to high-
level penicillin resistance in N. gonorrhoeae developed into a hypothesis that high-level 
resistance might not be caused by a single mutated gene at all. Results from the 
transcriptome analysis of MD4 and FA6140 show a striking difference in gene expression 
under normal circumstances. FA6140 expresses many genes at much higher levels, 
including several genes that have known functions in protecting against oxidative damage 
and aiding the bacterium in repairing the cell wall and DNA. Combined with the results 
from Chapter 4 demonstrating that bactericidal antibiotics kill N. gonorrhoeae through 
the production of hydroxyl radicals and oxidative stress mechanisms, this gene 
expression data provide a compelling argument for the hypothesis that FA6140, and other 
resistant strains, have evolved mechanisms to protect themselves from attack by 
bactericidal antibiotics.  
The problem of antibiotic resistance in N. gonorrhoeae is ongoing, and the 
development of resistance to every class of antibiotics used to treat gonococcal infections 
makes this an important public health issue. There is emerging resistance to ceftriaxone 
and cefixime, the current drugs used to treat gonorrhea and fears that gonorrhea may 
become untreatable are not unfounded. The findings described in this dissertation and the 
studies that are planned for the future will help to develop our knowledge about how 
resistance develops and how the pathogen responds to antibiotics, hopefully aiding in the 
design of new therapeutics. 
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